US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
EP0173494A3
(de)
*
|
1984-08-27 |
1987-11-25 |
The Board Of Trustees Of The Leland Stanford Junior University |
Chimäre Rezeptoren durch Verbindung und Expression von DNS
|
GB8422238D0
(en)
*
|
1984-09-03 |
1984-10-10 |
Neuberger M S |
Chimeric proteins
|
JPS61134325A
(ja)
*
|
1984-12-04 |
1986-06-21 |
Teijin Ltd |
ハイブリツド抗体遺伝子の発現方法
|
AU596585B2
(en)
*
|
1985-03-18 |
1990-05-10 |
Genelabs Incorporated |
Hybrid genes (eg. ig's & mhc proteins) via lambda library andplasmid casette vector
|
US5618920A
(en)
*
|
1985-11-01 |
1997-04-08 |
Xoma Corporation |
Modular assembly of antibody genes, antibodies prepared thereby and use
|
US5576195A
(en)
*
|
1985-11-01 |
1996-11-19 |
Xoma Corporation |
Vectors with pectate lyase signal sequence
|
EP0536566A1
(de)
*
|
1985-11-01 |
1993-04-14 |
Xoma Corporation |
Modulare Einheit von Antikörpergenen, daraus hergestellte Antikörper und Verwendung
|
DE3689123T2
(de)
*
|
1985-11-01 |
1994-03-03 |
Xoma Corp |
Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
|
GB2188941B
(en)
*
|
1986-04-14 |
1990-06-06 |
Bayer Ag |
Monoclonal antibodies recognizing human interleukin-2-receptor
|
CA1297434C
(en)
*
|
1986-04-14 |
1992-03-17 |
Kenji Murakami |
Method of producing peptides, recombinant plasmid for use in the same and animal cells transformed with the same
|
JPS63112995A
(ja)
*
|
1986-07-07 |
1988-05-18 |
セントコ−・インコ−ポレ−テッド |
腫瘍関連抗原に特異的なキメラ齧歯類/ヒト免疫グロブリン
|
US4954617A
(en)
*
|
1986-07-07 |
1990-09-04 |
Trustees Of Dartmouth College |
Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes
|
CA1340456C
(en)
*
|
1986-07-07 |
1999-03-23 |
Hubert J.P. Schoemaker |
Chimeric rodent/human immunoglobulins specific for tumor-associated antigens
|
JPH0698021B2
(ja)
*
|
1986-08-01 |
1994-12-07 |
帝人株式会社 |
マウス−ヒトキメラ抗体、それをコ−ドする発現型キメラdna配列、プラスミド及び細胞
|
JPS6336786A
(ja)
*
|
1986-07-31 |
1988-02-17 |
Teijin Ltd |
抗体l鎖発現型核酸塩基配列,プラスミド,細胞及びキメラ抗体l鎖
|
IL84285A
(en)
*
|
1986-10-27 |
1993-03-15 |
Int Genetic Engineering |
Chimeric antibody with specificity to human tumor antigen
|
US6893625B1
(en)
|
1986-10-27 |
2005-05-17 |
Royalty Pharma Finance Trust |
Chimeric antibody with specificity to human B cell surface antigen
|
IL85035A0
(en)
*
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
DE3855869T2
(de)
|
1987-02-20 |
1997-10-02 |
Genentech Inc |
Verfahren und Zubereitungen für die Verwendung von HIV-env-Polypeptiden und Antikörpern
|
US5132405A
(en)
*
|
1987-05-21 |
1992-07-21 |
Creative Biomolecules, Inc. |
Biosynthetic antibody binding sites
|
US5091513A
(en)
*
|
1987-05-21 |
1992-02-25 |
Creative Biomolecules, Inc. |
Biosynthetic antibody binding sites
|
US5258498A
(en)
*
|
1987-05-21 |
1993-11-02 |
Creative Biomolecules, Inc. |
Polypeptide linkers for production of biosynthetic proteins
|
DE3856559T2
(de)
*
|
1987-05-21 |
2004-04-29 |
Micromet Ag |
Multifunktionelle Proteine mit vorbestimmter Zielsetzung
|
US5834599A
(en)
*
|
1987-05-29 |
1998-11-10 |
Tanox Biosystems, Inc. |
Immunoconjugates which neutralize HIV-1 infection
|
ATE122237T1
(de)
*
|
1987-05-29 |
1995-05-15 |
Tanox Biosystems Inc |
Hiv-1 neutralisierende monoklonale antikörper.
|
US6657050B1
(en)
|
1987-05-29 |
2003-12-02 |
Tanox, Inc. |
Chimeric viral-neutralizing immunoglobulins
|
US5981278A
(en)
*
|
1987-05-29 |
1999-11-09 |
Tanox, Inc. |
Chimeric monoclonal antibodies which neutralize HIV-1 infection and their applications in therapy and prevention for AIDS
|
CA1341235C
(en)
*
|
1987-07-24 |
2001-05-22 |
Randy R. Robinson |
Modular assembly of antibody genes, antibodies prepared thereby and use
|
GB8720833D0
(en)
*
|
1987-09-04 |
1987-10-14 |
Celltech Ltd |
Recombinant dna product
|
GB8800077D0
(en)
*
|
1988-01-05 |
1988-02-10 |
Ciba Geigy Ag |
Novel chimeric antibodies
|
US5843708A
(en)
*
|
1988-01-05 |
1998-12-01 |
Ciba-Geigy Corporation |
Chimeric antibodies
|
US5750375A
(en)
*
|
1988-01-22 |
1998-05-12 |
Zymogenetics, Inc. |
Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions
|
US6018026A
(en)
*
|
1988-01-22 |
2000-01-25 |
Zymogenetics, Inc. |
Biologically active dimerized and multimerized polypeptide fusions
|
US5567584A
(en)
*
|
1988-01-22 |
1996-10-22 |
Zymogenetics, Inc. |
Methods of using biologically active dimerized polypeptide fusions to detect PDGF
|
EP0721983A1
(de)
*
|
1988-01-22 |
1996-07-17 |
ZymoGenetics, Inc. |
Verfahren zur herstellung von biologisch-aktive Dimerpeptiden
|
JP2646007B2
(ja)
|
1988-01-30 |
1997-08-25 |
財団法人 化学及血清療法研究所 |
抗hiv抗体可変領域をコードする遺伝子断片およびこれらを用いて発現された抗hivキメラ抗体ならびにその製法
|
JP3095168B2
(ja)
*
|
1988-02-05 |
2000-10-03 |
エル. モリソン,シェリー |
ドメイン‐変性不変部を有する抗体
|
US5770198A
(en)
*
|
1988-05-18 |
1998-06-23 |
The Research Foundation Of The State Of New York |
Platelet-specific chimeric 7E3 immunoglobulin
|
KR940009084B1
(ko)
*
|
1988-05-18 |
1994-09-29 |
체크 포인트 시스템스, 인코오퍼레이티드 |
자기 및 공명회로 검출용 안테나 시스템
|
US5609869A
(en)
*
|
1988-08-19 |
1997-03-11 |
The General Hospital Corporation |
Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically bind a thrombus, and methods of their production and use
|
US5811265A
(en)
*
|
1988-08-19 |
1998-09-22 |
The General Hospital Corporation |
Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically bind a thrombus, and methods of their production and use
|
EP0365209A3
(de)
*
|
1988-10-17 |
1990-07-25 |
Becton, Dickinson and Company |
Aminosäuresequenz des Anti-leu 3a
|
ES2052027T5
(es)
|
1988-11-11 |
2005-04-16 |
Medical Research Council |
Clonacion de secuencias de dominio variable de inmunoglobulina.
|
US5530101A
(en)
*
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
DE3900534A1
(de)
*
|
1989-01-10 |
1990-07-12 |
Boehringer Mannheim Gmbh |
Diagnostischer nachweis unter verwendung von chimaeren antikoerpern
|
US6291159B1
(en)
*
|
1989-05-16 |
2001-09-18 |
Scripps Research Institute |
Method for producing polymers having a preselected activity
|
US6291160B1
(en)
*
|
1989-05-16 |
2001-09-18 |
Scripps Research Institute |
Method for producing polymers having a preselected activity
|
US6291158B1
(en)
*
|
1989-05-16 |
2001-09-18 |
Scripps Research Institute |
Method for tapping the immunological repertoire
|
US6969586B1
(en)
|
1989-05-16 |
2005-11-29 |
Scripps Research Institute |
Method for tapping the immunological repertoire
|
US6291161B1
(en)
*
|
1989-05-16 |
2001-09-18 |
Scripps Research Institute |
Method for tapping the immunological repertiore
|
US6680192B1
(en)
|
1989-05-16 |
2004-01-20 |
Scripps Research Institute |
Method for producing polymers having a preselected activity
|
US5998378A
(en)
*
|
1989-08-16 |
1999-12-07 |
Chiron Corporation |
Compositions for the inhibition of TNF hormone formation and uses thereof
|
US5843693A
(en)
*
|
1989-08-16 |
1998-12-01 |
Chiron Corporation |
Assay method for screening for inhibitors of proTNF conversion
|
US6586222B1
(en)
|
1989-08-16 |
2003-07-01 |
Chiron Corporation |
Recombinant PR-3 and compositions thereof
|
US5196320A
(en)
*
|
1989-09-20 |
1993-03-23 |
Abbott Biotech, Inc. |
Method of producing engineered binding proteins
|
US6750325B1
(en)
|
1989-12-21 |
2004-06-15 |
Celltech R&D Limited |
CD3 specific recombinant antibody
|
US7037496B2
(en)
|
1989-12-27 |
2006-05-02 |
Centocor, Inc. |
Chimeric immunoglobulin for CD4 receptors
|
JP2564412B2
(ja)
*
|
1990-03-02 |
1996-12-18 |
財団法人癌研究会 |
薬剤耐性癌に対するキメラ抗体およびその製造
|
GB9022543D0
(en)
*
|
1990-10-17 |
1990-11-28 |
Wellcome Found |
Antibody production
|
DE4033120A1
(de)
*
|
1990-10-18 |
1992-04-23 |
Boehringer Mannheim Gmbh |
Verfahren zur herstellung von chimaeren antikoerpern
|
US5958413A
(en)
*
|
1990-11-01 |
1999-09-28 |
Celltech Limited |
Use of antibodies to TNF or fragments derived thereof and xanthine derivatives for combination therapy and compositions therefor
|
JP3510244B2
(ja)
|
1991-01-21 |
2004-03-22 |
エラン ファーマシューティカルス,インコーポレイテッド |
アルツハイマー病に関するテストおよびモデル
|
US7192584B2
(en)
|
1991-03-18 |
2007-03-20 |
Centocor, Inc. |
Methods of treating psoriasis with anti-TNF antibodies
|
US6277969B1
(en)
|
1991-03-18 |
2001-08-21 |
New York University |
Anti-TNF antibodies and peptides of human tumor necrosis factor
|
US6284471B1
(en)
|
1991-03-18 |
2001-09-04 |
New York University Medical Center |
Anti-TNFa antibodies and assays employing anti-TNFa antibodies
|
WO1992019759A1
(en)
*
|
1991-04-25 |
1992-11-12 |
Chugai Seiyaku Kabushiki Kaisha |
Reconstituted human antibody against human interleukin 6 receptor
|
US5939531A
(en)
*
|
1991-07-15 |
1999-08-17 |
Novartis Corp. |
Recombinant antibodies specific for a growth factor receptor
|
US5585103A
(en)
*
|
1991-07-25 |
1996-12-17 |
Idec Pharmaceutical Corporation |
Induction of cytotoxic T-lymphocyte responses
|
US5709860A
(en)
*
|
1991-07-25 |
1998-01-20 |
Idec Pharmaceuticals Corporation |
Induction of cytotoxic T-lymphocyte responses
|
CA2078539C
(en)
*
|
1991-09-18 |
2005-08-02 |
Kenya Shitara |
Process for producing humanized chimera antibody
|
US5441870A
(en)
*
|
1992-04-15 |
1995-08-15 |
Athena Neurosciences, Inc. |
Methods for monitoring cellular processing of β-amyloid precursor protein
|
US5604102A
(en)
*
|
1992-04-15 |
1997-02-18 |
Athena Neurosciences, Inc. |
Methods of screening for β-amyloid peptide production inhibitors
|
US5851787A
(en)
*
|
1992-04-20 |
1998-12-22 |
The General Hospital Corporation |
Nucleic acid encoding amyloid precursor-like protein and uses thereof
|
US6610493B1
(en)
|
1993-06-17 |
2003-08-26 |
Brigham And Women's Hospital |
Screening compounds for the ability to alter the production of amyloid-β peptide
|
US6270766B1
(en)
|
1992-10-08 |
2001-08-07 |
The Kennedy Institute Of Rheumatology |
Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
|
US5605811A
(en)
*
|
1992-10-26 |
1997-02-25 |
Athena Neurosciences, Inc. |
Methods and compositions for monitoring cellular processing of beta-amyloid precursor protein
|
WO1994015969A1
(en)
*
|
1993-01-14 |
1994-07-21 |
Juridical Foundation The Chemo-Sero-Therapeutic Research Institute |
Recombinant anti-hiv antibody and preparation thereof
|
KR100266554B1
(ko)
*
|
1993-01-14 |
2000-09-15 |
사꼬 미쓰오 |
재조합항-hiv항체및그의제조방법
|
AU6808194A
(en)
*
|
1993-05-31 |
1994-12-20 |
Chugai Seiyaku Kabushiki Kaisha |
Reconstructed human antibody against human interleukin-6
|
AU7732894A
(en)
*
|
1993-09-22 |
1995-04-10 |
Nichols Institute Diagnostics |
Graves' ophthalmopathy associated antibodies, graves' ophthalmopathy orbital antigen, and methods of use thereof
|
PT730643E
(pt)
|
1993-10-27 |
2001-06-29 |
Lilly Co Eli |
Animais transgenicos portadores do alelo de app com mutacao sueca
|
AU7949394A
(en)
*
|
1993-11-19 |
1995-06-06 |
Chugai Seiyaku Kabushiki Kaisha |
Reconstituted human antibody against human medulloblastomatous cell
|
WO1995024501A1
(en)
|
1994-03-07 |
1995-09-14 |
Cetus Oncology Corporation |
Compositions for the inhibition of tnf formation and uses thereof
|
US5874560A
(en)
|
1994-04-22 |
1999-02-23 |
The United States Of America As Represented By The Department Of Health And Human Services |
Melanoma antigens and their use in diagnostic and therapeutic methods
|
US6576236B1
(en)
|
1994-07-01 |
2003-06-10 |
Dana Farber Cancer Institute |
Methods for stimulating T cell responses by manipulating a common cytokine receptor γ chain
|
US5614609A
(en)
*
|
1994-10-20 |
1997-03-25 |
Carlos F. Ibanez |
Serine threonine kinase receptor
|
EP0789575B8
(de)
|
1994-11-02 |
2009-01-14 |
Allelix Neuroscience, Inc. |
Natrium-ionenkanäle spezifisch für das periphäre nervensystem, dna welche diese kodiert, wirkstoff-suche und methoden zu deren herstellung und verwendung
|
US7820798B2
(en)
|
1994-11-07 |
2010-10-26 |
Human Genome Sciences, Inc. |
Tumor necrosis factor-gamma
|
IL114615A0
(en)
|
1995-07-16 |
1995-11-27 |
Yeda Res & Dev |
Modulators of the function of fas receptors and other proteins
|
US6113898A
(en)
|
1995-06-07 |
2000-09-05 |
Idec Pharmaceuticals Corporation |
Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
|
US7153508B2
(en)
|
1995-06-07 |
2006-12-26 |
Biogen Idec Inc. |
Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4
|
US7175847B1
(en)
|
1995-06-07 |
2007-02-13 |
Biogen Idec Inc. |
Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4
|
US6717031B2
(en)
|
1995-06-07 |
2004-04-06 |
Kate Dora Games |
Method for selecting a transgenic mouse model of alzheimer's disease
|
US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
US6248555B1
(en)
|
1995-08-31 |
2001-06-19 |
The General Hospital Corporation |
Genetic alterations related to familial alzheimer's disease
|
JPH09124509A
(ja)
*
|
1995-10-27 |
1997-05-13 |
Sumitomo Electric Ind Ltd |
肝炎治療剤
|
US7888466B2
(en)
|
1996-01-11 |
2011-02-15 |
Human Genome Sciences, Inc. |
Human G-protein chemokine receptor HSATU68
|
DE69737326T2
(de)
|
1996-07-12 |
2007-11-22 |
Institut National De La Santé Et De La Recherche Médicale (Inserm) |
Transkriptions zwischen faktor-2 tif2
|
DK0961831T3
(da)
|
1996-08-16 |
2009-01-12 |
Human Genome Sciences Inc |
Humant alfa-endokin
|
PT939804E
(pt)
|
1996-10-25 |
2005-11-30 |
Human Genome Sciences Inc |
Neutroquina alfa
|
SI1019500T1
(sl)
|
1997-01-15 |
2007-02-28 |
Yeda Res & Dev |
Proteini, ki vezejo receptor 1 za ifn, dna, ki jih kodira, in postopki za regulacijo celicnega odziva na interferone
|
WO1998054206A1
(en)
|
1997-05-30 |
1998-12-03 |
Human Genome Sciences, Inc. |
32 human secreted proteins
|
ES2402947T3
(es)
|
1997-04-10 |
2013-05-10 |
Stichting Katholieke Universiteit University Medical Centre Nijmegen |
PCA3, genes PCA3 y métodos de uso
|
US6054567A
(en)
|
1997-04-11 |
2000-04-25 |
The United States Of America As Represented By The Department Of Health And Human Services |
Recombinant proteins of a pakistani strain of hepatitis E and their use in diagnostic methods and vaccines
|
JP2001524824A
(ja)
|
1997-04-16 |
2001-12-04 |
ミレニアム・フアーマシユーチカルズ・インコーポレーテツド |
Crspタンパク質(システインに富む分泌性タンパク質)、それらをコードする核酸分子およびその用途
|
EP0915980B1
(de)
|
1997-04-25 |
2009-08-05 |
Antigenics Inc. |
Charakterisierung von granulozytischer ehrlichia und methoden für ihre verwendung.
|
WO1998049311A2
(en)
|
1997-04-30 |
1998-11-05 |
De Novo Enzyme Corporation |
Ricin-like toxin variants for treatment of cancer, viral or parasitic infections
|
CA2206774A1
(en)
|
1997-06-16 |
1998-12-16 |
Rick E. Preddie |
"prionins", highly specific markers for noninvasive presymptomatic defection of tse diseases, and targets for therapeutic reagents to prevent and control tse diseases in animals and humans
|
EP1002068B1
(de)
|
1997-07-14 |
2009-09-09 |
University of Liège |
Mutationen im myostatingen steigern muskelmasse in säugetieren
|
DE19739685A1
(de)
|
1997-09-10 |
1999-03-11 |
Eichel Streiber Christoph Von |
Monoklonale Antikörper zur Therapie und Prophylaxe von Erkrankungen durch Clostridium difficile
|
US6635443B1
(en)
|
1997-09-17 |
2003-10-21 |
Human Genome Sciences, Inc. |
Polynucleotides encoding a novel interleukin receptor termed interleukin-17 receptor-like protein
|
EP1042343B1
(de)
|
1997-11-03 |
2008-01-23 |
Human Genome Sciences, Inc. |
Vegi, ein inhibitor der angiogenese und des tumorwachstums
|
CA2323776C
(en)
|
1998-03-19 |
2010-04-27 |
Human Genome Sciences, Inc. |
Cytokine receptor common gamma chain like
|
EP2301947A3
(de)
|
1999-02-26 |
2011-11-23 |
Millennium Pharmaceuticals, Inc. |
Sekretierte Proteine und Verwendungen dafür
|
EP2357192A1
(de)
|
1999-02-26 |
2011-08-17 |
Human Genome Sciences, Inc. |
Menschliches alpha-Endokin und Verfahren zu seiner Verwendung
|
US6531125B1
(en)
|
1999-03-02 |
2003-03-11 |
Twinstrand Therapeutics Inc. |
Antiviral ricin-like proteins
|
DE19915057A1
(de)
|
1999-04-01 |
2000-10-19 |
Forschungszentrum Borstel |
Monoklonale Antikörper gegen das humane Mcm3 Protein, Verfahren zu ihrer Herstellung und ihre Verwendung
|
CA2305716A1
(en)
|
1999-05-28 |
2000-11-28 |
University Of Guelph |
Method for assay of wbpm
|
IL130225A0
(en)
|
1999-05-31 |
2000-06-01 |
Yissum Res Dev Co |
Novel uses of antibodies against ache and peptides thereof
|
US7291714B1
(en)
|
1999-06-30 |
2007-11-06 |
Millennium Pharmaceuticals, Inc. |
Glycoprotein VI and uses thereof
|
US20040001826A1
(en)
|
1999-06-30 |
2004-01-01 |
Millennium Pharmaceuticals, Inc. |
Glycoprotein VI and uses thereof
|
MXPA02001877A
(es)
|
1999-08-23 |
2002-08-20 |
Dana Farber Cancer Inst Inc |
Pd-1, un receptor para b7-4, y usos del mismo.
|
MXPA02001911A
(es)
|
1999-08-24 |
2003-07-21 |
Medarex Inc |
Anticuerpos ctla-4 humanos y sus usos.
|
ATE321857T1
(de)
|
1999-09-29 |
2006-04-15 |
Diagnocure Inc |
Pca3 mrna in gutartigen und bösartigen prostatageweben
|
US7892541B1
(en)
|
1999-09-30 |
2011-02-22 |
Tumor Biology Investment Group, Inc. |
Soluble epidermal growth factor receptor isoforms
|
WO2001039722A2
(en)
|
1999-11-30 |
2001-06-07 |
Mayo Foundation For Medical Education And Research |
B7-h1, a novel immunoregulatory molecule
|
WO2001058949A2
(en)
|
2000-02-11 |
2001-08-16 |
Biogen, Inc. |
Heterologous polypeptide of the tnf family
|
EP2267026A1
(de)
|
2000-04-12 |
2010-12-29 |
Human Genome Sciences, Inc. |
Albuminfusionsproteine
|
US7560534B2
(en)
|
2000-05-08 |
2009-07-14 |
Celldex Research Corporation |
Molecular conjugates comprising human monoclonal antibodies to dendritic cells
|
EP1714661A3
(de)
|
2000-05-19 |
2012-03-14 |
The Center for Blood Research, INC. |
Verfahren zur Diagnose und Behandlung von hämostatischen Störungen durch Modulation der P-Selectin Aktivität
|
US20030031675A1
(en)
|
2000-06-06 |
2003-02-13 |
Mikesell Glen E. |
B7-related nucleic acids and polypeptides useful for immunomodulation
|
EP2251026A1
(de)
|
2000-06-08 |
2010-11-17 |
Immune Disease Institute, Inc. |
Verfahren und Zusammensetzungen zur Hemmung der immunoglobulinvermittelten Reperfusionsverletzung
|
EP1294949A4
(de)
|
2000-06-15 |
2004-08-25 |
Human Genome Sciences Inc |
Menschlicher tumornekrosefaktor delta und epsilon
|
AU6842701A
(en)
|
2000-06-16 |
2002-01-14 |
Human Genome Sciences Inc |
Antibodies that immunospecifically bind to blys
|
US6803211B2
(en)
|
2000-08-25 |
2004-10-12 |
Pfizer Inc. |
Methods and compositions for diagnosing and treating disorders involving angiogenesis
|
AU2001288478B2
(en)
|
2000-08-25 |
2006-11-02 |
Basf Plant Science Gmbh |
Plant polynucleotides encoding prenyl proteases
|
DE60140457D1
(de)
|
2000-09-01 |
2009-12-24 |
Blood Res Center |
Veränderte, in gewünschter konformation stabilisierte polypeptide und verfahren zu deren herstellung
|
UA83458C2
(uk)
|
2000-09-18 |
2008-07-25 |
Байоджен Айдек Ма Інк. |
Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
|
DE60140903D1
(de)
|
2000-10-18 |
2010-02-04 |
Brigham & Womens Hospital |
E-selectin/l-selectin-liganden-polypeptide hämatopoetischer zellen und verfahren zu deren verwendung
|
AU4155602A
(en)
|
2000-11-01 |
2002-06-18 |
Elusys Therapeutics Inc |
Method of producing biospecific molecules by protein trans-splicing
|
JP4368196B2
(ja)
|
2000-11-17 |
2009-11-18 |
ユニバーシティー オブ ロチェスター |
真核細胞において免疫グロブリン分子を製造および同定するインビトロにおける方法
|
US6989247B2
(en)
|
2000-11-28 |
2006-01-24 |
Celltech R & D, Inc. |
Compositions and methods for diagnosing or treating psoriasis
|
BR0115715A
(pt)
|
2000-11-28 |
2004-02-03 |
Wyeth Corp |
Análise de expressão de ácidos nucleìcos e polipeptìdeos úteis na diagnose e tratamento de câncer da próstata
|
EP2295606A1
(de)
|
2000-11-28 |
2011-03-16 |
Wyeth LLC |
Expressionsanalyse von KIAA Nukleinsäuren und Polypeptiden, geeignet zur Diagnose und zur Behandlung von Prostatakrebs
|
US20030124534A1
(en)
|
2000-12-08 |
2003-07-03 |
Luca Rastelli |
Method of detecting and treating Tuberous Sclerosis Complex associated disorders
|
US7445802B2
(en)
|
2000-12-26 |
2008-11-04 |
Yeda Research And Development Co. Ltd |
Site-specific in situ generation of allicin using a targeted alliinase delivery system for the treatment of cancers, tumors, infectious diseases and other allicin-sensitive diseases
|
US6815166B2
(en)
|
2001-02-23 |
2004-11-09 |
Dana-Farber Cancer Institute, Inc. |
HIN-1, a tumor suppressor gene
|
MXPA03008959A
(es)
|
2001-04-02 |
2004-10-15 |
Wyeth Corp |
Pd-1, un receptor para b7-4 y sus usos.
|
JP2005501518A
(ja)
|
2001-04-16 |
2005-01-20 |
ワイス・ホールディングズ・コーポレイション |
ポリペプチド抗原をコードしている新規ストレプトコッカスニューモニアエオープンリーディングフレームおよびその使用
|
US7256257B2
(en)
|
2001-04-30 |
2007-08-14 |
Seattle Genetics, Inc. |
Pentapeptide compounds and uses related thereto
|
US7744882B2
(en)
|
2001-05-31 |
2010-06-29 |
Tumor Biology Investment Group, Inc. |
Soluble ErbB3 methods of detection and antibodies
|
US7745398B2
(en)
|
2001-05-31 |
2010-06-29 |
Tumor Biology Investment Group, Inc. |
Soluble ErbB3 and treatment of cancer
|
WO2002098897A2
(en)
|
2001-06-01 |
2002-12-12 |
Cornell Research Foundation, Inc. |
Modified antibodies to prostate-specific membrane antigen and uses thereof
|
US7514078B2
(en)
|
2001-06-01 |
2009-04-07 |
Cornell Research Foundation, Inc. |
Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
|
JP2005500034A
(ja)
|
2001-06-20 |
2005-01-06 |
プロション バイオテク リミテッド |
受容体型タンパク質チロシンキナーゼ活性化を遮断する抗体、そのスクリーニング方法、及びその使用
|
TWI334439B
(en)
|
2001-08-01 |
2010-12-11 |
Centocor Inc |
Anti-tnf antibodies, compositions, methods and uses
|
US20040142325A1
(en)
|
2001-09-14 |
2004-07-22 |
Liat Mintz |
Methods and systems for annotating biomolecular sequences
|
DK1432431T3
(en)
|
2001-10-04 |
2017-07-10 |
Genetics Inst Llc |
Methods and compositions for modulating interleukin-21 activity
|
MX339524B
(es)
|
2001-10-11 |
2016-05-30 |
Wyeth Corp |
Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
|
DE10151511A1
(de)
|
2001-10-18 |
2003-05-08 |
Basf Lynx Bioscience Ag |
ee3-Proteinfamilie und zugrundeliegende DNA-Sequenzen
|
DK1461300T3
(da)
|
2001-11-30 |
2011-10-24 |
Biogen Idec Inc |
Antistoffer mod kemotaktiske monocytproteiner
|
CN1630514A
(zh)
|
2001-12-05 |
2005-06-22 |
贝勒医学院 |
通过调节交感神经紧张性控制骨形成的方法和组合物
|
GB0129105D0
(en)
|
2001-12-05 |
2002-01-23 |
Celltech R&D Ltd |
Expression control using variable intergenic sequences
|
US7858297B2
(en)
|
2001-12-18 |
2010-12-28 |
Centre National De La Recherche Scientifique Cnrs |
Chemokine-binding protein and methods of use
|
AU2002361385B2
(en)
|
2001-12-18 |
2009-11-19 |
Centre National De La Recherche Scientifique Cnrs |
Novel death associated proteins of the THAP family and related Par4 pathways involved in apoptosis control
|
AU2002359721A1
(en)
|
2001-12-19 |
2003-07-09 |
Bristol-Myers Squibb Company |
Pichia pastoris formate dehydrogenase and uses therefor
|
WO2003057159A2
(en)
|
2001-12-31 |
2003-07-17 |
Dana-Farber Cancer Institute, Inc. |
Psoriasin expression by breast epithelial cells
|
WO2003076455A2
(en)
|
2002-03-05 |
2003-09-18 |
Ramot At Tel-Aviv University Ltd. |
Immunizing composition and method for inducing an immune response against the ss-secretase cleavage site of amyloid precursor protein
|
GB0207533D0
(en)
|
2002-04-02 |
2002-05-08 |
Oxford Glycosciences Uk Ltd |
Protein
|
AU2003226065B2
(en)
|
2002-04-12 |
2009-02-26 |
Ludwig Institute For Cancer Research, Ltd |
Recombinant anti-interleukin-9 antibodies
|
US8088889B2
(en)
|
2002-05-02 |
2012-01-03 |
David Lovejoy |
Teneurin c-terminal associated peptides (TCAP) and uses thereof
|
PT1361439E
(pt)
|
2002-05-07 |
2007-02-28 |
Pasteur Institut |
Rastreio de peptidos inibindo a ligação de pp1c as proteínas blc-2, bcl-x e bcl-w
|
US7563882B2
(en)
|
2002-06-10 |
2009-07-21 |
University Of Rochester |
Polynucleotides encoding antibodies that bind to the C35 polypeptide
|
AU2003247551C1
(en)
|
2002-06-17 |
2010-12-09 |
Thrasos Innovation, Inc. |
Single domain TDF-related compounds and analogs thereof
|
US7250551B2
(en)
|
2002-07-24 |
2007-07-31 |
President And Fellows Of Harvard College |
Transgenic mice expressing inducible human p25
|
WO2004010957A2
(en)
|
2002-07-31 |
2004-02-05 |
Seattle Genetics, Inc. |
Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
|
EP1569514A4
(de)
|
2002-08-16 |
2007-10-31 |
|
Tumorassoziiertes antigen, peptide davon, und deren verwendung als antitumorimpfstoffe
|
JP2006514823A
(ja)
|
2002-08-20 |
2006-05-18 |
ミレニアム ファーマスーティカルズ インク |
子宮頸癌の同定、評価、予防および治療を行うための組成物、キットおよび方法
|
US7785608B2
(en)
|
2002-08-30 |
2010-08-31 |
Wyeth Holdings Corporation |
Immunogenic compositions for the prevention and treatment of meningococcal disease
|
EP2112229A3
(de)
|
2002-11-25 |
2009-12-02 |
Sequenom, Inc. |
Verfahren zum Identifizieren des Brustkrebsrisikos und zugehörige Behandlungen
|
EP1581629B1
(de)
|
2002-12-06 |
2015-04-01 |
Millennium Pharmaceuticals, Inc. |
Verfahren zur identifizierung,beurteilung und behandlung von patienten mit einer proteasomen inhibitions therapie
|
ATE471335T1
(de)
|
2002-12-23 |
2010-07-15 |
Vical Inc |
Impfstoffe gegen infektionen mit dem humanen zytomegalivirus auf grundlage von codonoptimierten polynukleotiden
|
US8557957B2
(en)
|
2003-01-03 |
2013-10-15 |
Elizabeth Kornecki |
Methods of treating disorders by administration of F11 receptor antagonists
|
US20050265992A1
(en)
|
2003-01-03 |
2005-12-01 |
The Research Foundation Of State University Of New York |
F11 receptor (F11R) antagonists as therapeutic agents
|
CA2513675A1
(en)
|
2003-01-17 |
2004-08-05 |
The Johns Hopkins University |
Methods of identifying modulators of cellular glycosylation using gtrap3-18
|
AU2004209578A1
(en)
|
2003-02-07 |
2004-08-19 |
Diagnocure Inc. |
Method to detect prostate cancer in a sample
|
US20040180387A1
(en)
|
2003-03-13 |
2004-09-16 |
Fujirebio Diagnostics, Inc. |
Detection of urinary mesothelin-/megakaryocyte potentiating factor-related peptides for assessment of ovarian cancer
|
GB0309126D0
(en)
|
2003-04-17 |
2003-05-28 |
Neutec Pharma Plc |
Clostridium difficile focussed antibodies
|
CN100417414C
(zh)
|
2003-04-30 |
2008-09-10 |
苏黎世大学 |
免疫毒素在制备治疗头颈鳞状上皮细胞癌或膀胱癌药物中的应用
|
SI2374819T1
(sl)
|
2003-05-12 |
2017-09-29 |
Helion Biotech Aps |
Protitelesa proteina MASP-2
|
US20050014932A1
(en)
|
2003-05-15 |
2005-01-20 |
Iogenetics, Llc |
Targeted biocides
|
US8080642B2
(en)
|
2003-05-16 |
2011-12-20 |
Vical Incorporated |
Severe acute respiratory syndrome DNA compositions and methods of use
|
US7892563B2
(en)
|
2003-05-20 |
2011-02-22 |
Wyeth Holdings Corporation |
Methods for treatment of severe acute respiratory syndrome (SARS)
|
WO2005004794A2
(en)
|
2003-06-09 |
2005-01-20 |
Alnylam Pharmaceuticals Inc. |
Method of treating neurodegenerative disease
|
WO2005012526A1
(en)
|
2003-08-04 |
2005-02-10 |
The Hospital For Sick Children |
Lafora's disease gene
|
IL158287A0
(en)
|
2003-10-07 |
2004-05-12 |
Yeda Res & Dev |
Antibodies to nik, their preparation and use
|
CN1964986A
(zh)
|
2003-10-07 |
2007-05-16 |
千年药品公司 |
用于鉴定、评价、预防和治疗卵巢癌的核酸分子和蛋白质
|
BR122018071808B8
(pt)
|
2003-11-06 |
2020-06-30 |
Seattle Genetics Inc |
conjugado
|
US20070276049A1
(en)
|
2003-11-11 |
2007-11-29 |
Schlievert Patrick M |
Regulation of Cell Membrane-Mediated Effects
|
US7427670B2
(en)
|
2003-12-19 |
2008-09-23 |
Cytochroma Inc. |
Cytochrome P450 24 (CYP24) monoclonal antibody and methods and uses thereof
|
EP1710310A4
(de)
|
2003-12-30 |
2007-02-21 |
Suntory Ltd |
Neuartiger streptococcus mutans im serum und dessen nutzung
|
PL2311873T3
(pl)
|
2004-01-07 |
2019-01-31 |
Novartis Vaccines And Diagnostics, Inc. |
Przeciwciało monoklonalne specyficzne wobec M-CSF i jego zastosowania
|
EP2444805A3
(de)
|
2004-01-21 |
2012-06-20 |
Fujirebio America, Inc. |
Erkennung von Mesothelin-/Megakaryozyten zur Potenzierung von faktorbezogenen Peptiden in peritonealer Flüssigkeit zur Bewertung des Peritoneum und Peritonealhöhle
|
CA2553946C
(en)
|
2004-02-06 |
2019-02-26 |
University Of Massachusetts |
Antibodies against clostridium difficile toxins and uses thereof
|
CA2560066A1
(en)
|
2004-03-01 |
2005-09-15 |
The Cbr Institute For Biomedical Research, Inc. |
Natural igm antibodies and inhibitors thereof
|
EP1756162A1
(de)
|
2004-03-23 |
2007-02-28 |
Biogen Idec MA Inc. |
Rezeptor-kupplungsmittel und ihre therapeutischen verwendungen
|
WO2005097832A2
(en)
|
2004-03-31 |
2005-10-20 |
Genentech, Inc. |
Humanized anti-tgf-beta antibodies
|
WO2005116270A2
(en)
|
2004-05-18 |
2005-12-08 |
Vical Incorporated |
Influenza virus vaccine composition and method of use
|
EP1598428A1
(de)
|
2004-05-18 |
2005-11-23 |
Georg Dewald |
Verfahren und Kits zum Nachweis von erblichen angioedema typ III
|
US8367038B2
(en)
|
2004-05-23 |
2013-02-05 |
HMI Medical Innovations, LLC |
Therameutin modulators
|
EP2789342A1
(de)
|
2004-06-17 |
2014-10-15 |
Thrasos Innovation, Inc. |
Verbindungen im Zusammenhang mit TDF und Analoga davon
|
GB0414054D0
(en)
|
2004-06-23 |
2004-07-28 |
Owen Mumford Ltd |
Improvements relating to automatic injection devices
|
US20070264277A1
(en)
|
2004-07-22 |
2007-11-15 |
Dirk Behrens |
Compositions and Methods of Use for Mgd-Csf in Disease Treatment
|
TWI384069B
(zh)
|
2004-08-27 |
2013-02-01 |
Pfizer Ireland Pharmaceuticals |
多胜肽之製法
|
US7300773B2
(en)
|
2004-08-27 |
2007-11-27 |
Wyeth Research Ireland Limited |
Production of TNFR-Ig
|
TWI374935B
(en)
|
2004-08-27 |
2012-10-21 |
Pfizer Ireland Pharmaceuticals |
Production of α-abeta
|
EP3428191A1
(de)
|
2004-10-06 |
2019-01-16 |
Mayo Foundation for Medical Education and Research |
B7-h1 und pd-1 in der behandlung von nierenzellkarzinom
|
ES2715776T3
(es)
|
2004-11-12 |
2019-06-06 |
Seattle Genetics Inc |
Auristatinas que tienen una unidad de ácido aminobenzoico en el extremo N
|
CA2491067A1
(en)
|
2004-12-24 |
2006-06-24 |
Stichting Katholieke Universiteit |
Mrna rations in urinary sediments and/or urine as a prognostic marker for prostate cancer
|
GT200600031A
(es)
|
2005-01-28 |
2006-08-29 |
|
Formulacion anticuerpo anti a beta
|
BRPI0608210A2
(pt)
|
2005-02-14 |
2010-11-09 |
Wyeth Corp |
métodos de diagnóstico de um distúrbio relacionado com il-17f em um indivìduo e de seleção de compostos capazes de inibirem a ligação de il-17f em il-17r, uso de um antagonista de il-17f, composição farmacêutica, e, adjuvante de vacina
|
ES2716874T3
(es)
|
2005-03-23 |
2019-06-17 |
Genmab As |
Anticuerpos contra cd38 para el tratamiento del mieloma múltiple
|
GT200600148A
(es)
|
2005-04-14 |
2006-11-22 |
|
Metodos para el tratamiento y la prevencion de fibrosis
|
AU2006236225C1
(en)
|
2005-04-19 |
2013-05-02 |
Seagen Inc. |
Humanized anti-CD70 binding agents and uses thereof
|
US8034902B2
(en)
|
2005-05-04 |
2011-10-11 |
Quark Pharmaceuticals, Inc. |
Recombinant antibodies against CD55 and CD59 and uses thereof
|
US8431110B2
(en)
|
2005-05-23 |
2013-04-30 |
Hmi Medical Innovations, Llc. |
Compounds and method of identifying, synthesizing, optimizing and profiling protein modulators
|
US20100074884A1
(en)
|
2005-05-31 |
2010-03-25 |
Duska Scientific Co. |
Inhibition of neuronal damage
|
CN104926938B
(zh)
|
2005-06-17 |
2019-06-04 |
惠氏有限责任公司 |
纯化含Fc区蛋白的方法
|
US8343928B2
(en)
|
2005-07-07 |
2013-01-01 |
Seattle Genetics, Inc. |
Monomethylvaline compounds having phenylalanine side-chain replacements at the C-terminus
|
HUE057936T2
(hu)
|
2005-07-18 |
2022-06-28 |
Seagen Inc |
Béta-glükuronid-linker-hatóanyag konjugátumok
|
SG164379A1
(en)
|
2005-07-21 |
2010-09-29 |
Genmab As |
Potency assays for antibody drug substance binding to an fc receptor
|
WO2007016285A2
(en)
|
2005-07-28 |
2007-02-08 |
Novartis Ag |
M-csf specific monoclonal antibody and uses thereof
|
ES2537527T3
(es)
|
2005-09-20 |
2015-06-09 |
Thrasos Innovation, Inc. |
Compuestos relacionados con el TDF y análogos de los mismos
|
AU2006294481B2
(en)
|
2005-09-28 |
2012-12-20 |
Becton, Dickinson And Company |
Detection of lysophosphatidylcholine for prognosis or diagnosis of a systemic inflammatory condition
|
ES2526705T3
(es)
|
2005-10-25 |
2015-01-14 |
The Johns Hopkins University |
Métodos y composiciones para el tratamiento de síndrome de Marfan y trastornos asociados
|
EP1948235B1
(de)
|
2005-11-01 |
2013-08-28 |
AbbVie Biotechnology Ltd |
Methoden zur bestimmung der wirksamkeit von adalimumab bei patienten mit morbus bechterew mit ctx-ii und mmp3 als biomarker
|
EP1945261A4
(de)
|
2005-11-07 |
2010-05-12 |
Scripps Research Inst |
Zusammensetzungen und verfahren zur steuerung der spezifität von gewebefaktor-signalisierungen
|
EP1948238B1
(de)
|
2005-11-10 |
2013-08-28 |
Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College |
Zusammensetzungen und Verfahren zur Behandlung von Sucht und anderen neuropsychiatrischen Erkrankungen
|
ATE547709T1
(de)
|
2005-11-14 |
2012-03-15 |
Metamol Theranostics Llc |
Tumorinvasionsfördernde peptidsequenz
|
US20070264687A1
(en)
|
2005-12-15 |
2007-11-15 |
Min-Yuan Chou |
Recombinant triplex scaffold-based polypeptides
|
US10183986B2
(en)
|
2005-12-15 |
2019-01-22 |
Industrial Technology Research Institute |
Trimeric collagen scaffold antibodies
|
EP3438131B1
(de)
|
2006-02-10 |
2022-03-16 |
Life Technologies Corporation |
Modifizierung von oligosacchariden und etikettierung von proteinen
|
US20100233818A1
(en)
|
2006-02-17 |
2010-09-16 |
Atsuo Sekiyama |
Biological Load Indicator and Method of Measuring Biological Load
|
TWI417301B
(zh)
|
2006-02-21 |
2013-12-01 |
Wyeth Corp |
對抗人類介白素-22(il-22)之抗體及其用途
|
TW200744634A
(en)
|
2006-02-21 |
2007-12-16 |
Wyeth Corp |
Methods of using antibodies against human IL-22
|
EP2374472B9
(de)
|
2006-03-16 |
2019-06-12 |
Dyax Corp. |
Zusammensetzungen und Verfahren zur Behandlung von Augenerkrankungen
|
RU2429014C2
(ru)
|
2006-03-31 |
2011-09-20 |
Массачусетс Инститьют Оф Текнолоджи |
Лечение опухолей, экспрессирующих мутантные рецепторы egf
|
SG170837A1
(en)
|
2006-04-05 |
2011-05-30 |
Abbott Biotech Ltd |
Antibody purification
|
EP2666479A3
(de)
|
2006-04-10 |
2014-03-26 |
Abbott Biotechnology Ltd |
Anwendungen und Zusammensetzungen zur Behandlung von juveniler rheumatoider Arthritis
|
CA2564435A1
(en)
|
2006-04-10 |
2007-10-10 |
Abbott Biotechnology Ltd. |
Methods for monitoring and treating intestinal disorders
|
EP2007426A4
(de)
|
2006-04-10 |
2010-06-16 |
Abbott Biotech Ltd |
Anwendungen und zusammensetzungen zur behandlung von psoriasis-arthritis
|
US8293245B2
(en)
|
2006-04-20 |
2012-10-23 |
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. |
Methods and compositions based on Shiga toxin type 1 protein
|
AU2007257162A1
(en)
|
2006-06-05 |
2007-12-13 |
Cancer Care Ontario |
Assessment of risk for colorectal cancer
|
GB0611116D0
(en)
|
2006-06-06 |
2006-07-19 |
Oxford Genome Sciences Uk Ltd |
Proteins
|
EP2046384A4
(de)
|
2006-06-15 |
2009-12-02 |
Fibron Ltd |
Antikörper zur blockierung der fibroblasten-wachstumsfaktor-rezeptor-aktivierung und anwendungsverfahren dafür
|
ATE544468T1
(de)
|
2006-06-28 |
2012-02-15 |
Yeda Res & Dev |
Caspase-8 und wundheilung
|
EP2043711A4
(de)
|
2006-06-30 |
2017-08-30 |
AbbVie Biotechnology Ltd |
Automatische injektionsvorrichtung
|
US7572618B2
(en)
|
2006-06-30 |
2009-08-11 |
Bristol-Myers Squibb Company |
Polynucleotides encoding novel PCSK9 variants
|
JP5605895B2
(ja)
|
2006-07-04 |
2014-10-15 |
ゲンマブ エー/エス |
Copdを処置するためのcd20結合分子
|
KR101495549B1
(ko)
|
2006-07-13 |
2015-02-25 |
와이어쓰 엘엘씨 |
당단백질의 생산
|
ES2452067T3
(es)
|
2006-08-04 |
2014-03-31 |
Novartis Ag |
Anticuerpo específico para EPHB3 y usos del mismo
|
PT2059535E
(pt)
|
2006-08-18 |
2014-01-29 |
Novartis Ag |
Anticorpos específicos do prlr e suas utulizações
|
US7951776B2
(en)
|
2006-09-01 |
2011-05-31 |
American Type Culture Collection |
Methods for treatment of type 1 diabetes
|
US20090203602A1
(en)
|
2006-09-01 |
2009-08-13 |
Cohava Gelber |
Compositions and methods for diagnosis and treatment of type 2 diabetes
|
DK2081595T3
(da)
|
2006-09-26 |
2019-07-15 |
Genmab As |
Anti-cd38 plus corticosteroid plus et ikke-corticosteroid kemoterapeutikum til behandling af tumorer
|
US20120282245A1
(en)
|
2006-10-03 |
2012-11-08 |
Biogen Idec Ma Inc. |
Biomarkers and assays for the treatment of cancer
|
JP2010506839A
(ja)
|
2006-10-12 |
2010-03-04 |
ワイス エルエルシー |
乳光の低減を伴う方法および組成物
|
CA2666317C
(en)
|
2006-11-03 |
2013-08-06 |
Wyeth |
Glycolysis-inhibiting substances in cell culture
|
US20110294782A1
(en)
|
2006-11-10 |
2011-12-01 |
Massachusetts Institute Of Technology |
Small molecule pak inhibitors
|
EP2094282A4
(de)
|
2006-11-15 |
2010-05-05 |
Functional Genetics Inc |
Antikörper gegen tsg101 und verwendungen davon zur behandlung von virusinfektionen
|
EP2095826B1
(de)
|
2006-11-17 |
2012-12-26 |
The Research Foundation for Microbial Diseases of Osaka University |
Nervenelongationspromoter und elongationshemmer
|
ES2523915T5
(es)
|
2006-12-01 |
2022-05-26 |
Seagen Inc |
Agentes de unión a la diana variantes y usos de los mismos
|
KR20140119831A
(ko)
|
2006-12-07 |
2014-10-10 |
노파르티스 아게 |
Ephb3에 대한 길항제 항체
|
AR064642A1
(es)
|
2006-12-22 |
2009-04-15 |
Wyeth Corp |
Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
|
AU2008205330B2
(en)
|
2007-01-08 |
2014-07-03 |
Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services |
SLCO1B3 genotype
|
AU2008209404B2
(en)
|
2007-01-22 |
2012-08-16 |
Genentech, Inc. |
Polyelectrolyte precipitation and purification of antibodies
|
WO2008104803A2
(en)
|
2007-02-26 |
2008-09-04 |
Oxford Genome Sciences (Uk) Limited |
Proteins
|
EP3118221B1
(de)
|
2007-02-26 |
2019-08-21 |
Oxford BioTherapeutics Ltd |
Proteine
|
AU2008223133A1
(en)
|
2007-03-02 |
2008-09-12 |
Wyeth |
Use of copper and glutamate in cell culture for production of polypeptides
|
EP2243834A1
(de)
|
2007-03-05 |
2010-10-27 |
Cancer Care Ontario |
Abschätzung des Kolorektalkarzinomrisikos
|
US20100267934A1
(en)
|
2007-05-31 |
2010-10-21 |
Genmab A/S |
Stable igg4 antibodies
|
WO2008154543A2
(en)
|
2007-06-11 |
2008-12-18 |
Abbott Biotechnology Ltd. |
Methods for treating juvenile idiopathic arthritis
|
US20080317768A1
(en)
|
2007-06-21 |
2008-12-25 |
Boeing Company |
Bioconjugated nanoparticles
|
EP2185688A4
(de)
|
2007-08-06 |
2010-08-25 |
Burnham Inst Medical Research |
Znf206: ein neuer regulator der selbsterneuerung und pluripotenz embryonaler stammzellen
|
US7951785B2
(en)
|
2007-09-21 |
2011-05-31 |
California Institute Of Technology |
NFIA in glial fate determination, glioma therapy and astrocytoma treatment
|
EP2205625B1
(de)
|
2007-09-24 |
2012-09-12 |
Cornell University |
Immunogene proteine aus der genomabgeleiteten äusseren membran von leptospira und darauf basierende zusammensetzungen und verfahren
|
US8431352B2
(en)
|
2007-09-27 |
2013-04-30 |
Virus Ikagaku Kenkyusho Inc. |
Diagnosis of mood disorders by detecting latent infection with human herpesvirus-6
|
GB0719231D0
(en)
|
2007-10-03 |
2007-11-14 |
Oxford Genome Sciences Uk Ltd |
Protein
|
KR101603076B1
(ko)
|
2007-12-28 |
2016-03-14 |
프로테나 바이오사이언시즈 리미티드 |
아밀로이드증의 치료 및 예방
|
DK3043181T3
(da)
|
2008-01-15 |
2020-05-04 |
Univ Leland Stanford Junior |
Markører af akutte myeloid-leukæmi-stamceller
|
CN102037007A
(zh)
|
2008-01-25 |
2011-04-27 |
奥尔胡斯大学 |
选择性外部位点抑制papp-a对igfbp-4的活性
|
PL2842575T3
(pl)
|
2008-03-18 |
2018-02-28 |
Seattle Genetics, Inc. |
Koniugaty aurystatyny lek łącznik
|
EP3329931B1
(de)
|
2008-04-18 |
2022-06-08 |
The General Hospital Corporation |
Immuntherapien mit selbst-zusammensetzenden vakzinen
|
CA2723197C
(en)
|
2008-05-02 |
2017-09-19 |
Seattle Genetics, Inc. |
Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
|
US8741287B2
(en)
|
2008-06-18 |
2014-06-03 |
Abbott Laboratories |
PlGF-1 assay and kits and components thereof
|
KR20110031343A
(ko)
|
2008-06-20 |
2011-03-25 |
와이어쓰 엘엘씨 |
베타-용혈성 스트렙토코커스 균주로부터 유래된 orf1358을 사용하는 조성물 및 방법
|
DK2732823T3
(da)
|
2008-06-25 |
2019-09-16 |
H Lundbeck As |
Modulering af TrpV : Vps10p-domæne-receptorsystemet til behandlingen af smerte
|
EP2315779A2
(de)
|
2008-07-09 |
2011-05-04 |
Biogen Idec MA Inc. |
Antikörper gegen lingo oder fragmente davon enthaltende zusammensetzungen
|
EP2344180A2
(de)
|
2008-09-23 |
2011-07-20 |
Wyeth LLC |
Verfahren zur vorhersage der produktion von aktivierenden signalen durch vernetzende bindungsproteine
|
DK2342226T3
(en)
|
2008-09-26 |
2016-09-26 |
Dana Farber Cancer Inst Inc |
HUMAN ANTI-PD-1, PD-L1 AND PD-L2 ANTIBODIES AND APPLICATIONS THEREOF
|
TR201802130T4
(tr)
|
2008-10-10 |
2018-03-21 |
Beth Israel Deaconess Medical Ct Inc |
Biyokimyasal olarak stabilize edilmiş HIV-1 env trimer aşısı.
|
MX2011004558A
(es)
|
2008-10-29 |
2011-06-01 |
Wyeth Llc |
Procedimientos para la purificacion de moleculas de union a antigeno de un unico dominio.
|
US9393304B2
(en)
|
2008-10-29 |
2016-07-19 |
Ablynx N.V. |
Formulations of single domain antigen binding molecules
|
AU2009313615B2
(en)
|
2008-11-05 |
2012-11-29 |
Regents Of The University Of Minnesota |
Multicomponent immunogenic composition for the prevention of beta-hemolytic streptococcal (BHS) disease
|
US20100183620A1
(en)
|
2008-11-26 |
2010-07-22 |
Kaumudi Bhawe |
Compositions and methods for regulating collagen and smooth muscle actin expression by serpine2
|
EP2374813A1
(de)
|
2008-12-03 |
2011-10-12 |
Proyecto de Biomedicina Cima, S.L. |
Verwendung von phenollöslichen modulinen zur entwicklung von impfstoffen
|
US8703125B2
(en)
|
2008-12-19 |
2014-04-22 |
H. Lundbeck A/S |
Modulation of the Vps10p-domain receptor family for the treatment of mental and behavioural disorders
|
US8349325B2
(en)
|
2008-12-23 |
2013-01-08 |
Abbott Laboratories |
Soluble FMS-like tyrosine kinase-1 (sFLT-1) antibody and related composition, kit, methods of using, and materials and method for making
|
CN102341411A
(zh)
|
2008-12-31 |
2012-02-01 |
比奥根艾迪克Ma公司 |
抗-淋巴细胞毒素抗体
|
US9181315B2
(en)
|
2009-01-08 |
2015-11-10 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for induced brown fat differentiation
|
WO2010084408A2
(en)
|
2009-01-21 |
2010-07-29 |
Oxford Biotherapeutics Ltd. |
Pta089 protein
|
WO2010088522A2
(en)
|
2009-01-30 |
2010-08-05 |
Ab Biosciences, Inc. |
Novel lowered affinity antibodies and uses therefor
|
WO2010091182A2
(en)
|
2009-02-04 |
2010-08-12 |
Molecular Innovations |
Methods for screening candidate agents for modulating prorenin and renin, assays for detecting prorenin, and antibodies used therein
|
JP2010213694A
(ja)
|
2009-03-12 |
2010-09-30 |
Wyeth Llc |
PKN3/RhoC高分子複合体およびその使用方法
|
JPWO2010110346A1
(ja)
|
2009-03-24 |
2012-10-04 |
独立行政法人理化学研究所 |
白血病幹細胞マーカー
|
WO2010112034A2
(en)
|
2009-04-02 |
2010-10-07 |
Aarhus Universitet |
Compositions and methods for treatment and diagnosis of synucleinopathies
|
EP3248618A1
(de)
|
2009-04-22 |
2017-11-29 |
Massachusetts Institute Of Technology |
Angeborene immununterdrückung mit ermöglichung der wiederholten verabreichung von langen rna-molekülen
|
EP2421559B1
(de)
|
2009-04-24 |
2016-07-20 |
Vanderbilt University |
Anti-tgf-beta-aktivierung von knochenwachstum
|
MX2011011541A
(es)
|
2009-04-29 |
2012-02-28 |
Abbott Biotech Ltd |
Dispositivo de inyeccion automatico.
|
EP2424891B1
(de)
|
2009-04-29 |
2014-06-11 |
The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. |
Monoklonale erg-antikörper
|
EP2272979A1
(de)
|
2009-06-30 |
2011-01-12 |
Centre National de la Recherche Scientifique (CNRS) |
Verfahren zum Testen einer Person, die eine Prädisposition für Krebs aufzuweisen scheint
|
CA2766861A1
(en)
|
2009-07-09 |
2011-01-13 |
F. Hoffmann-La Roche Ag |
In vivo tumor vasculature imaging
|
WO2011048598A1
(en)
|
2009-10-22 |
2011-04-28 |
Yeda Research And Development Co. Ltd. |
Compositions and methods for treating aspergillosis
|
US20120282177A1
(en)
|
2009-11-02 |
2012-11-08 |
Christian Rohlff |
ROR1 as Therapeutic and Diagnostic Target
|
US9588121B2
(en)
|
2009-11-06 |
2017-03-07 |
Go Therapeutics, Inc. |
Method for early detection of cancer
|
CA2778953C
(en)
|
2009-11-13 |
2020-01-14 |
Dana-Farber Cancer Institute, Inc. |
Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1
|
WO2011075524A1
(en)
|
2009-12-15 |
2011-06-23 |
Abbott Biotechnology Ltd |
Improved firing button for automatic injection device
|
US20110150891A1
(en)
|
2009-12-16 |
2011-06-23 |
Philip Bosch |
Methods of Treating Interstitial Cystitis
|
AU2011207210A1
(en)
|
2010-01-22 |
2012-08-16 |
Dana-Farber Cancer Institute, Inc. |
Compositions,kits, and methods for identification, assessment, prevention, and therapy of metabolic disorders
|
JP6101489B2
(ja)
|
2010-01-28 |
2017-03-22 |
アブ バイオサイエンシズ インコーポレイテッド |
親和性が低下した抗体およびそれを作製する方法
|
JP2013518590A
(ja)
|
2010-02-02 |
2013-05-23 |
アボツト・バイオテクノロジー・リミテツド |
TNF−α阻害剤を用いる処置に対する応答性を予測するための方法および組成物
|
TWI518325B
(zh)
|
2010-02-04 |
2016-01-21 |
自治醫科大學 |
對alk抑制劑具有先抗性或後抗性癌症的識別、判斷和治療
|
RU2577125C2
(ru)
|
2010-02-10 |
2016-03-10 |
Фуджифилм Ри Фарма Ко., Лтд. |
Меченное радиоактивным металлом антитело против кадгерина
|
EP3056510B1
(de)
|
2010-03-03 |
2018-10-03 |
The University Of British Columbia |
Oligomer-spezifisches amyloid-beta-epitop und antikörper
|
WO2011119484A1
(en)
|
2010-03-23 |
2011-09-29 |
Iogenetics, Llc |
Bioinformatic processes for determination of peptide binding
|
WO2013040142A2
(en)
|
2011-09-16 |
2013-03-21 |
Iogenetics, Llc |
Bioinformatic processes for determination of peptide binding
|
US20150231215A1
(en)
|
2012-06-22 |
2015-08-20 |
Randolph J. Noelle |
VISTA Antagonist and Methods of Use
|
US10745467B2
(en)
|
2010-03-26 |
2020-08-18 |
The Trustees Of Dartmouth College |
VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
|
CN107098958B
(zh)
|
2010-03-26 |
2021-11-05 |
达特茅斯大学理事会 |
Vista调节性t细胞介体蛋白、vista结合剂及其用途
|
CA2793778A1
(en)
|
2010-04-05 |
2011-11-13 |
Wyeth Llc |
Biomarkers for p13k-driven cancer
|
RU2695703C2
(ru)
|
2010-04-21 |
2019-07-25 |
Эббви Байотекнолоджи Лтд. |
Носимое устройство для автоматической инъекции для управляемой подачи терапевтических агентов
|
WO2011146727A1
(en)
|
2010-05-19 |
2011-11-24 |
Philip Bosch |
Methods of treating interstitial cystitis
|
LT2575884T
(lt)
|
2010-06-03 |
2018-09-25 |
Abbvie Biotechnology Ltd |
Panaudojimai ir kompozicijos, skirti pūlingo hidradenito (hs) gydymui
|
WO2012009705A1
(en)
|
2010-07-15 |
2012-01-19 |
Zyngenia, Inc. |
Ang-2 binding complexes and uses thereof
|
EP2593476A2
(de)
|
2010-07-16 |
2013-05-22 |
Ablynx N.V. |
Modifizierte einzeldomänen-antigen-bindungsmoleküle und ihre verwendung
|
EP2420250A1
(de)
|
2010-08-13 |
2012-02-22 |
Universitätsklinikum Münster |
Anti-Syndecan-4-Antikörper
|
JP2013535981A
(ja)
|
2010-08-20 |
2013-09-19 |
ワイス・エルエルシー |
成長因子不含適合細胞の細胞培養
|
ES2850973T3
(es)
|
2010-08-23 |
2021-09-01 |
Wyeth Llc |
Formulaciones estables de antígenos rLP2086 de Neisseria meningitidis
|
WO2012032489A1
(en)
|
2010-09-10 |
2012-03-15 |
Wyeth Llc |
Non-lipidated variants of neisseria meningitidis orf2086 antigens
|
UA112062C2
(uk)
|
2010-10-04 |
2016-07-25 |
Бьорінгер Інгельхайм Інтернаціональ Гмбх |
Cd33-зв'язувальний агент
|
WO2012064743A2
(en)
|
2010-11-08 |
2012-05-18 |
The Johns Hopkins University |
Methods for improving heart function
|
US20120115244A1
(en)
|
2010-11-09 |
2012-05-10 |
Abbott Laboratories |
Materials and methods for immunoassay of pterins
|
WO2012071513A2
(en)
|
2010-11-24 |
2012-05-31 |
Hong Gao |
Expanding hematopoietic stem cells
|
RU2013131825A
(ru)
|
2011-01-10 |
2015-02-20 |
Зе Реджентс Оф Зе Юниверсити Оф Мичиган |
Ингибитор фактора стволовых клеток
|
US20150018408A1
(en)
|
2013-07-10 |
2015-01-15 |
The Regents Of The University Of Michigan |
Therapeutic antibodies and uses thereof
|
BR112013018905B1
(pt)
|
2011-01-24 |
2021-07-13 |
Abbvie Biotechnology Ltd |
Dispositivos de injeção automática que têm superfícies de pega sobremoldadas.
|
CN103501859B
(zh)
|
2011-03-02 |
2017-08-25 |
博格有限责任公司 |
基于细胞的探询式分析及其应用
|
WO2012131053A1
(en)
|
2011-03-30 |
2012-10-04 |
Ablynx Nv |
Methods of treating immune disorders with single domain antibodies against tnf-alpha
|
AU2012239961A1
(en)
|
2011-04-08 |
2013-10-24 |
Biogen Ma Inc. |
Biomarkers predictive of therapeutic responsiveness to IFNbeta and uses thereof
|
JP6152090B2
(ja)
|
2011-04-21 |
2017-06-21 |
ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド,ア ボディー コーポレイトTHE REGENTS OF THE UNIVERSITY OF COLORADO,a body corporate |
視神経脊髄炎を処置するための組成物および方法
|
EP3020428A1
(de)
|
2011-04-21 |
2016-05-18 |
AbbVie Inc. |
Tragbare automatische injektionsvorrichtung zur gesteuerten verabreichung von therapeutika
|
WO2012162561A2
(en)
|
2011-05-24 |
2012-11-29 |
Zyngenia, Inc. |
Multivalent and monovalent multispecific complexes and their uses
|
PL2726094T3
(pl)
|
2011-06-28 |
2017-06-30 |
Oxford Biotherapeutics Ltd |
Cel terapeutyczny i diagnostyczny
|
WO2013014538A2
(en)
|
2011-07-25 |
2013-01-31 |
American University In Cairo |
Single-domain antibodies and graphene coated magnetic metal nanoparticles conjugate and methods for using the same
|
BR112014004162A2
(pt)
|
2011-08-22 |
2018-04-24 |
Cangene Corp |
anticorpos contra clostridium difficile
|
AU2012298884B2
(en)
|
2011-08-23 |
2017-11-16 |
Foundation Medicine, Inc. |
Novel KIF5B-RET fusion molecules and uses thereof
|
CA2846667A1
(en)
|
2011-09-06 |
2013-03-14 |
Guy L. Reed |
Serpinf2-binding molecules and methods of use
|
US10093705B2
(en)
|
2011-09-13 |
2018-10-09 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for brown fat induction and activity using FNDC5
|
CA2846432A1
(en)
|
2011-09-23 |
2013-03-28 |
Amgen Research (Munich) Gmbh |
Bispecific binding molecules for 5t4 and cd3
|
US20140322758A1
(en)
|
2011-10-21 |
2014-10-30 |
Pfizer Inc. |
Addition of iron to improve cell culture
|
TWI679212B
(zh)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對bcma之e3以及cd3的結合分子
|
US8828401B2
(en)
|
2011-11-17 |
2014-09-09 |
Pfizer Inc. |
Cytotoxic peptides and antibody drug conjugates thereof
|
WO2013078455A2
(en)
|
2011-11-23 |
2013-05-30 |
The Board Of Regents Of The University Of Texas System |
Proteomic identification of antibodies
|
EP2599496A1
(de)
|
2011-11-30 |
2013-06-05 |
Kenta Biotech AG |
Neuartige Targets von Acinetobacter baumannii
|
WO2013128027A1
(en)
|
2012-03-01 |
2013-09-06 |
Amgen Research (Munich) Gmbh |
Long life polypeptide binding molecules
|
NZ628449A
(en)
|
2012-03-09 |
2016-04-29 |
Pfizer |
Neisseria meningitidis compositions and methods thereof
|
SA115360586B1
(ar)
|
2012-03-09 |
2017-04-12 |
فايزر انك |
تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
|
SI2831261T1
(en)
|
2012-03-27 |
2018-01-31 |
F.Hoffmann-La Roche |
A process for the production of low-level recombinant proteins DHNA (1,4-dihydroxy-2-naphthoate)
|
WO2013152011A1
(en)
|
2012-04-02 |
2013-10-10 |
Ab Biosciences, Inc. |
Novel human control antibodies and uses therefor
|
EA038600B1
(ru)
|
2012-04-02 |
2021-09-21 |
Берг Ллк |
Основанные на клетках перекрестные анализы и их применение
|
CN104470541A
(zh)
|
2012-05-14 |
2015-03-25 |
比奥根艾迪克Ma公司 |
用于治疗涉及运动神经元的疾患的lingo-2拮抗剂
|
JP6423340B2
(ja)
|
2012-05-15 |
2018-11-14 |
シアトル ジェネティクス,インコーポレイティド |
自己安定化リンカー結合体
|
US9890215B2
(en)
|
2012-06-22 |
2018-02-13 |
King's College London |
Vista modulators for diagnosis and treatment of cancer
|
GB201213652D0
(en)
|
2012-08-01 |
2012-09-12 |
Oxford Biotherapeutics Ltd |
Therapeutic and diagnostic target
|
WO2014022759A1
(en)
|
2012-08-03 |
2014-02-06 |
Dana-Farber Cancer Institute, Inc. |
Agents that modulate immune cell activation and methods of use thereof
|
CA2884704C
(en)
|
2012-09-07 |
2023-04-04 |
Randolph J. Noelle |
Vista modulators for diagnosis and treatment of cancer
|
AU2013329372B2
(en)
|
2012-10-08 |
2018-07-12 |
St. Jude Children's Research Hospital |
Therapies based on control of regulatory T cell stability and function via a Neuropilin-1:Semaphorin axis
|
EP3750560A3
(de)
|
2012-10-09 |
2021-03-24 |
Biogen MA Inc. |
Kombinationstherapien und deren verwendungen zur behandlung von demyelinisierungserkrankungen
|
WO2014066733A2
(en)
|
2012-10-25 |
2014-05-01 |
Life Technologies Corporation |
Methods and compositions for enzyme-mediated site-specific radiolabeling of glycoproteins
|
WO2014071358A2
(en)
|
2012-11-05 |
2014-05-08 |
Foundation Medicine, Inc. |
Novel ntrk1 fusion molecules and uses thereof
|
JP6355641B2
(ja)
|
2012-11-05 |
2018-07-11 |
ファイザー・インク |
スプライソスタチン類似体
|
TW201726746A
(zh)
|
2012-11-07 |
2017-08-01 |
輝瑞股份有限公司 |
抗切口3(anti-notch3)抗體及抗體-藥物共軛體
|
WO2014089177A2
(en)
|
2012-12-04 |
2014-06-12 |
Massachusetts Institute Of Technology |
Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
|
CA2898326C
(en)
|
2013-01-18 |
2022-05-17 |
Foundation Medicine, Inc. |
Methods of treating cholangiocarcinoma
|
GB201302447D0
(en)
|
2013-02-12 |
2013-03-27 |
Oxford Biotherapeutics Ltd |
Therapeutic and diagnostic target
|
US10398661B2
(en)
|
2013-02-28 |
2019-09-03 |
The Board Of Regents Of The University Of Texas System |
Methods for classifying a cancer as susceptible to TMEPAI-directed therapies and treating such cancers
|
JP6446377B2
(ja)
|
2013-03-08 |
2018-12-26 |
ファイザー・インク |
免疫原性融合ポリペプチド
|
AU2014236309A1
(en)
|
2013-03-14 |
2015-10-29 |
Ren Liu |
Cancer treatment using antibodies that bing cell surface GRP78
|
EP2968550B1
(de)
|
2013-03-14 |
2018-11-14 |
Ffe Therapeutics LLC |
Zusammensetzungen und verfahren zur behandlung von angiogenesebedingten erkrankungen
|
WO2014144600A2
(en)
|
2013-03-15 |
2014-09-18 |
Viktor Roschke |
Multivalent and monovalent multispecific complexes and their uses
|
AR095374A1
(es)
|
2013-03-15 |
2015-10-14 |
Amgen Res (Munich) Gmbh |
Moléculas de unión para bcma y cd3
|
JP6431038B2
(ja)
|
2013-03-15 |
2018-11-28 |
ザイムワークス インコーポレイティド |
細胞毒性及び抗有糸分裂性化合物とその使用方法
|
EP3293275B1
(de)
|
2013-06-06 |
2021-08-04 |
Dana-Farber Cancer Institute, Inc. |
Zusammensetzung und verfahren zur identifikation, beurteilung, vorbeugung und behandlung von krebs mit pd-l1-isoformen
|
US9587032B2
(en)
|
2013-06-12 |
2017-03-07 |
The Board Of Trustees Of The Leland Stanford Junior University |
IgE antibodies for the inhibition of tumor metastasis
|
US9428748B2
(en)
|
2013-06-17 |
2016-08-30 |
Hong Gao |
Method of expanding hematopoietic stem cells
|
EP3027225B1
(de)
|
2013-07-31 |
2021-03-24 |
Dana-Farber Cancer Institute, Inc. |
Zusammensetzungen und verfahren zur modulierung der thermogenese mit transformierender wachstumsfaktor alpha
|
US20160193308A1
(en)
|
2013-09-04 |
2016-07-07 |
Osaka University |
Dpp-4-targeting vaccine for treating diabetes
|
CA2923129C
(en)
|
2013-09-08 |
2020-06-09 |
Pfizer Inc. |
Neisseria meningitidis compositions and methods thereof
|
US10570204B2
(en)
|
2013-09-26 |
2020-02-25 |
The Medical College Of Wisconsin, Inc. |
Methods for treating hematologic cancers
|
CA2921707C
(en)
|
2013-10-15 |
2023-03-28 |
Seattle Genetics, Inc. |
Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
|
CN105940115B
(zh)
|
2013-11-15 |
2021-07-06 |
巴斯德研究所 |
恶性疟原虫青蒿素耐药性的分子标记物
|
US9644023B2
(en)
|
2013-12-09 |
2017-05-09 |
New York University |
Compositions and methods for phagocyte delivery of anti-staphylococcal agents
|
EP3083670A2
(de)
|
2013-12-17 |
2016-10-26 |
Westfälische Wilhelms-Universität Münster |
Vorrichtung und verfahren zur behandlung einer pruritusartigen hauterkrankung
|
TWI777502B
(zh)
|
2013-12-19 |
2022-09-11 |
美商西雅圖遺傳學公司 |
與標的-藥物結合物併用之亞甲基胺基甲酸酯連接物
|
EP2960252A1
(de)
|
2014-06-26 |
2015-12-30 |
Institut Pasteur |
Phospholipase zur Behandlung von Immunosuppression
|
MX369173B
(es)
|
2013-12-24 |
2019-10-30 |
Janssen Pharmaceutica Nv |
Anticuerpos y fragmentos anti-vista.
|
US11014987B2
(en)
|
2013-12-24 |
2021-05-25 |
Janssen Pharmaceutics Nv |
Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
|
KR102384740B1
(ko)
|
2013-12-27 |
2022-04-07 |
자임워크스 인코포레이티드 |
약물 접합체를 위한 설폰아마이드-함유 연결 시스템
|
KR101836756B1
(ko)
|
2013-12-27 |
2018-03-08 |
오사카 유니버시티 |
Il-17a를 표적화하는 백신
|
WO2015103026A2
(en)
|
2014-01-03 |
2015-07-09 |
The Regents Of The University Of Michigan |
Treatment of neurological disorders
|
EP3094736A4
(de)
|
2014-01-14 |
2017-10-25 |
Dana-Farber Cancer Institute, Inc. |
Zusammensetzungen und verfahren zur identifikation, beurteilung, vorbeugung und behandlung von melanom mit pd-l1-isoformen
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
CN106459055B
(zh)
|
2014-01-27 |
2019-11-01 |
辉瑞大药厂 |
双功能细胞毒类药剂
|
MX2016009954A
(es)
|
2014-01-29 |
2017-02-23 |
Dana Farber Cancer Inst Inc |
Anticuerpos contra el dominio extracelular de muc1-c (muc1-c/ecd).
|
EP4047015A1
(de)
|
2014-02-11 |
2022-08-24 |
Visterra, Inc. |
Antikörpermoleküle gegen denguevirus und verwendungen davon
|
SG10202001468UA
(en)
|
2014-02-17 |
2020-04-29 |
Seattle Genetics Inc |
Hydrophilic antibody-drug conjugates
|
WO2015127140A2
(en)
|
2014-02-19 |
2015-08-27 |
Jody Berry |
Marburg monoclonal antibodies
|
EP3116909B1
(de)
|
2014-03-14 |
2019-11-13 |
Novartis Ag |
Antikörpermoleküle gegen lag-3 und verwendungen davon
|
WO2015140708A1
(en)
|
2014-03-19 |
2015-09-24 |
Pfizer Inc. |
Method of cell culture
|
BR112016020009A2
(pt)
|
2014-04-10 |
2017-10-17 |
Obi Pharma Inc |
anticorpo, composição farmacêutica, método para inibir a proliferação de células cancerígenas, hibridoma
|
CA2983794A1
(en)
|
2014-04-25 |
2015-10-29 |
The Brigham And Women's Hospital, Inc. |
Methods to manipulate alpha-fetoprotein (afp)
|
AU2015259516B2
(en)
|
2014-05-13 |
2020-05-28 |
Bavarian Nordic A/S |
Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and a monoclonal antibody against TIM-3
|
CN107073109B
(zh)
|
2014-06-11 |
2021-08-06 |
凯西·A·格林 |
Vista激动剂和拮抗剂抑制或增强体液免疫的用途
|
EP3511413B1
(de)
|
2014-07-25 |
2022-09-07 |
Theravectys |
Lentivirale vektoren zur regulierten expression eines chimären antigenrezeptormoleküls
|
CA2956471A1
(en)
|
2014-07-31 |
2016-02-04 |
Amgen Research (Munich) Gmbh |
Optimized cross-species specific bispecific single chain antibody constructs
|
WO2016016415A1
(en)
|
2014-07-31 |
2016-02-04 |
Amgen Research (Munich) Gmbh |
Bispecific single chain antibody construct with enhanced tissue distribution
|
UY36245A
(es)
|
2014-07-31 |
2016-01-29 |
Amgen Res Munich Gmbh |
Constructos de anticuerpos para cdh19 y cd3
|
US10392444B2
(en)
|
2014-08-08 |
2019-08-27 |
Oncoquest, Inc. |
Tumor antigen specific antibodies and TLR3 stimulation to enhance the performance of checkpoint interference therapy of cancer
|
WO2016025202A1
(en)
|
2014-08-14 |
2016-02-18 |
The Regents Of The University Of Colorado |
Antibody-sirna conjugates and uses therefor
|
DK3189132T3
(da)
|
2014-09-04 |
2020-08-10 |
Stemcell Tech Inc |
Opløselige antistofkomplekser til T-celle- eller NK-celle-aktivering og -ekspansion
|
EP3925622A1
(de)
|
2014-09-13 |
2021-12-22 |
Novartis AG |
Kombinationstherapien
|
EP3110447B1
(de)
|
2014-09-16 |
2020-04-29 |
Synermore Biologics Co., Ltd. |
Anti-egfr-antikörper und verwendungen davon
|
HUE057768T2
(hu)
|
2014-09-17 |
2022-06-28 |
Zymeworks Inc |
Citotoxikus és antimitotikus vegyületek és azok alkalmazásának módszerei
|
CA2963281A1
(en)
|
2014-10-03 |
2016-04-07 |
Novartis Ag |
Combination therapies
|
JP6574257B2
(ja)
|
2014-10-07 |
2019-09-11 |
アン アンド ロバート エイチ. ルーリー チルドレンズ ホスピタル オブ シカゴ |
新規の抗Nodal抗体及びその使用方法
|
EP4245376A3
(de)
|
2014-10-14 |
2023-12-13 |
Novartis AG |
Antikörpermoleküle gegen pd-l1 und verwendungen davon
|
BR112017009297B1
(pt)
|
2014-11-05 |
2024-02-15 |
Annexon, Inc |
Anticorpos antifator de complemento c1q humanizados, composição farmacêutica e kit compreendendo os mesmos, uso terapêutico destes,polinucleotídeo isolado, célula hospedeira isolada, bem como métodos in vitro para detectar sinapses
|
WO2016090347A1
(en)
|
2014-12-05 |
2016-06-09 |
Immunext, Inc. |
Identification of vsig8 as the putative vista receptor and its use thereof to produce vista/vsig8 modulators
|
EP3229837A4
(de)
|
2014-12-08 |
2018-05-30 |
Dana-Farber Cancer Institute, Inc. |
Verfahren zur hochregulierung von immunantworten unter verwendung von kombinationen aus anti-rgmb- und anti-pd1-wirkstoffen
|
EP3233918A1
(de)
|
2014-12-19 |
2017-10-25 |
Novartis AG |
Kombinationstherapien
|
US10435467B2
(en)
|
2015-01-08 |
2019-10-08 |
Biogen Ma Inc. |
LINGO-1 antagonists and uses for treatment of demyelinating disorders
|
AU2016206682B2
(en)
|
2015-01-14 |
2021-11-11 |
The Brigham And Women's Hospital, Inc. |
Treatment of cancer with anti-LAP monoclonal antibodies
|
CN107405410B
(zh)
|
2015-01-15 |
2021-08-10 |
OncoQuest制药有限公司 |
增加抗癌剂向靶递送的方法
|
DK3254110T3
(da)
|
2015-02-03 |
2020-05-18 |
Ventana Med Syst Inc |
Histokemisk test til vurdering af ekspression af programmeret død-ligand 1 (pd-l1)
|
BR112017017460A2
(pt)
|
2015-02-19 |
2018-04-10 |
Pfizer Inc. |
composições de neisseria meningitidis e métodos das mesmas
|
US10479825B2
(en)
|
2015-02-25 |
2019-11-19 |
Vanderbilt University |
Antibody-mediated neutralization of Marburg virus
|
WO2016151432A1
(en)
|
2015-03-20 |
2016-09-29 |
Pfizer Inc. |
Bifunctional cytotoxic agents containing the cti pharmacophore
|
EP4276116A3
(de)
|
2015-04-17 |
2024-01-17 |
Amgen Research (Munich) GmbH |
Bispezifische antikörperkonstrukte für cdh3 und cd3
|
WO2016170022A1
(en)
|
2015-04-21 |
2016-10-27 |
Institut Gustave Roussy |
Therapeutic methods, products and compositions inhibiting znf555
|
BR112017027870A2
(pt)
|
2015-06-24 |
2018-08-28 |
Janssen Pharmaceutica Nv |
anticorpos e fragmentos anti-vista
|
JOP20200312A1
(ar)
|
2015-06-26 |
2017-06-16 |
Novartis Ag |
الأجسام المضادة للعامل xi وطرق الاستخدام
|
LT3317301T
(lt)
|
2015-07-29 |
2021-07-26 |
Novartis Ag |
Kombinuotos terapijos, apimančios antikūno molekules prieš lag-3
|
US20180207273A1
(en)
|
2015-07-29 |
2018-07-26 |
Novartis Ag |
Combination therapies comprising antibody molecules to tim-3
|
EP3328418A1
(de)
|
2015-07-29 |
2018-06-06 |
Novartis AG |
Kombinationstherapien mit antikörpermolekülen gegen pd-1
|
TWI744242B
(zh)
|
2015-07-31 |
2021-11-01 |
德商安美基研究(慕尼黑)公司 |
Egfrviii及cd3抗體構築體
|
TWI796283B
(zh)
|
2015-07-31 |
2023-03-21 |
德商安美基研究(慕尼黑)公司 |
Msln及cd3抗體構築體
|
TWI717375B
(zh)
|
2015-07-31 |
2021-02-01 |
德商安美基研究(慕尼黑)公司 |
Cd70及cd3抗體構築體
|
TW202346349A
(zh)
|
2015-07-31 |
2023-12-01 |
德商安美基研究(慕尼黑)公司 |
Dll3及cd3抗體構築體
|
TWI829617B
(zh)
|
2015-07-31 |
2024-01-21 |
德商安美基研究(慕尼黑)公司 |
Flt3及cd3抗體構築體
|
US11384138B2
(en)
|
2015-08-19 |
2022-07-12 |
Rutgers, The State University Of New Jersey |
Methods of generating antibodies
|
AU2016315873B2
(en)
|
2015-09-04 |
2022-08-18 |
Primatope Therapeutics Inc. |
Humanized anti-CD40 antibodies and uses thereof
|
EP3922645A1
(de)
|
2015-09-15 |
2021-12-15 |
Scholar Rock, Inc. |
Anti-pro/latentes-myostatin-antikörper und verwendungen davon
|
CA2999224C
(en)
|
2015-09-23 |
2023-10-24 |
Pfizer Inc. |
Cells and method of cell culture
|
CN108472362B
(zh)
|
2015-10-07 |
2022-03-29 |
台湾浩鼎生技股份有限公司 |
新颖糖类抗体、医药组成物及其用途
|
WO2017066561A2
(en)
|
2015-10-16 |
2017-04-20 |
President And Fellows Of Harvard College |
Regulatory t cell pd-1 modulation for regulating t cell effector immune responses
|
AU2016343978A1
(en)
|
2015-10-29 |
2018-05-17 |
Dana-Farber Cancer Institute, Inc. |
Methods for identification, assessment, prevention, and treatment of metabolic disorders using PM20D1 and N-lipidated amino acids
|
WO2017079215A1
(en)
|
2015-11-03 |
2017-05-11 |
Glycomimetics, Inc. |
Methods and compositions for the production of monoclonal antibodies, hematopoietic stem cells, and methods of using the same
|
EP3165532B1
(de)
|
2015-11-03 |
2018-12-19 |
Industrial Technology Research Institute |
Auristatin derivate, linker-arzneimittel und ligandenarzneimittelkonjugate
|
WO2017083296A1
(en)
|
2015-11-09 |
2017-05-18 |
The Children's Hospital Of Philadelphia |
Glypican 2 as a cancer marker and therapeutic target
|
WO2017083515A2
(en)
|
2015-11-10 |
2017-05-18 |
Visterra, Inc. |
Antibody molecule-drug conjugates and uses thereof
|
MY197345A
(en)
|
2015-11-25 |
2023-06-14 |
Visterra Inc |
Antibody molecules to april and uses thereof
|
US11793880B2
(en)
|
2015-12-04 |
2023-10-24 |
Seagen Inc. |
Conjugates of quaternized tubulysin compounds
|
AU2016363013B2
(en)
|
2015-12-04 |
2022-03-10 |
Seagen Inc. |
Conjugates of quaternized tubulysin compounds
|
US20200261573A1
(en)
|
2015-12-17 |
2020-08-20 |
Novartis Ag |
Combination of c-met inhibitor with antibody molecule to pd-1 and uses thereof
|
MX2018007423A
(es)
|
2015-12-17 |
2018-11-09 |
Novartis Ag |
Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas.
|
CN109152811A
(zh)
|
2015-12-18 |
2019-01-04 |
阿吉尔瓦克斯公司 |
与xCT肽相关的组合物和方法
|
WO2017120523A2
(en)
|
2016-01-08 |
2017-07-13 |
Scholar Rock, Inc. |
Anti-pro/latent myostatin antibodies and methods of use thereof
|
WO2017134547A1
(en)
|
2016-02-01 |
2017-08-10 |
Pfizer Inc. |
Tubulysin analogs and methods for their preparation
|
PL3411404T3
(pl)
|
2016-02-03 |
2023-02-13 |
Amgen Research (Munich) Gmbh |
Konstrukty dwuswoistych przeciwciał wobec PSMA i CD3 angażujących komórki T
|
US10301391B2
(en)
|
2016-02-03 |
2019-05-28 |
Amgen Research (Munich) Gmbh |
BCMA and CD3 bispecific T cell engaging antibody constructs
|
EA039859B1
(ru)
|
2016-02-03 |
2022-03-21 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкты антител, связывающие egfrviii и cd3
|
EP3410849B1
(de)
|
2016-02-05 |
2023-07-05 |
Institut Pasteur |
Verwendung von inhibitoren von adam12 als adjuvanzien in tumortherapien
|
US10465003B2
(en)
|
2016-02-05 |
2019-11-05 |
Janssen Biotech, Inc. |
Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
|
BR112018016461A2
(pt)
|
2016-02-12 |
2019-10-01 |
Janssen Pharmaceutica Nv |
anticorpos e fragmentos anti-vista, usos dos mesmos e métodos de identificação dos mesmos
|
CA3017356A1
(en)
|
2016-03-10 |
2017-09-14 |
Aperisys, Inc. |
Antigen-binding fusion proteins with modified hsp70 domains
|
CA3055555A1
(en)
|
2016-03-11 |
2017-09-14 |
Scholar Rock, Inc. |
Tgf.beta.1-binding immunoglobulins and use thereof
|
JP7155008B2
(ja)
|
2016-03-14 |
2022-10-18 |
ウニヴァーシテテット イ オスロ |
変化されたFcRnを有する改変された免疫グロブリン
|
WO2017158421A1
(en)
|
2016-03-14 |
2017-09-21 |
University Of Oslo |
Anti-viral engineered immunoglobulins
|
WO2017158436A1
(en)
|
2016-03-17 |
2017-09-21 |
Oslo Universitetssykehus Hf |
Fusion proteins targeting tumour associated macrophages for treating cancer
|
JP7082604B2
(ja)
|
2016-03-21 |
2022-06-08 |
マレンゴ・セラピューティクス,インコーポレーテッド |
多重特異性および多機能性分子ならびにその使用
|
SG11201807827VA
(en)
|
2016-03-25 |
2018-10-30 |
Seattle Genetics Inc |
Process for the preparation of pegylated drug-linkers and intermediates thereof
|
WO2017165736A1
(en)
|
2016-03-25 |
2017-09-28 |
Visterra, Inc. |
Formulation of antibody molecules to dengue virus
|
MX2018012129A
(es)
|
2016-04-05 |
2018-12-17 |
Pfizer |
Proceso de cultivo celular.
|
CN109414489B
(zh)
|
2016-04-08 |
2022-08-16 |
埃缇健康公司D/B/A泽尔拜尔 |
网蛋白-1结合抗体及其用途
|
US20170298119A1
(en)
|
2016-04-15 |
2017-10-19 |
Visterra, Inc. |
Antibody molecules to zika virus and uses thereof
|
MX2018012469A
(es)
|
2016-04-15 |
2019-07-04 |
Immunext Inc |
Anticuerpos vista antihumanos y uso de los mismos.
|
JOP20170091B1
(ar)
|
2016-04-19 |
2021-08-17 |
Amgen Res Munich Gmbh |
إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية
|
US10918627B2
(en)
|
2016-05-11 |
2021-02-16 |
Massachusetts Institute Of Technology |
Convergent and enantioselective total synthesis of Communesin analogs
|
TW201802121A
(zh)
|
2016-05-25 |
2018-01-16 |
諾華公司 |
抗因子XI/XIa抗體之逆轉結合劑及其用途
|
EP3472210A1
(de)
|
2016-06-17 |
2019-04-24 |
Life Technologies Corporation |
Stellenspezifische vernetzung von antikörpern
|
US11780924B2
(en)
|
2016-06-21 |
2023-10-10 |
University Of Oslo |
HLA binding vaccine moieties and uses thereof
|
AU2017297404A1
(en)
|
2016-07-13 |
2019-01-24 |
Biogen Ma Inc. |
Dosage regimens of LINGO-1 antagonists and uses for treatment of demyelinating disorders
|
BR112019001989A2
(pt)
|
2016-08-02 |
2019-08-20 |
Visterra Inc |
polipeptídeos projetados e usos dos mesmos
|
WO2018025168A1
(en)
|
2016-08-03 |
2018-02-08 |
Pfizer Inc. |
Heteroaryl sulfone-based conjugation handles, methods for their preparation, and their use in synthesizing antibody drug conjugates
|
TW201808343A
(zh)
|
2016-08-09 |
2018-03-16 |
美商西雅圖遺傳學公司 |
具有改善之生理化學性質之具自我穩定連接子之藥物結合物
|
ES2919927T3
(es)
|
2016-08-10 |
2022-07-29 |
Pasteur Institut |
Métodos y reactivos para la detección del paludismo por Plasmodium falciparum resistente a la piperaquina
|
KR20200136503A
(ko)
|
2016-08-15 |
2020-12-07 |
노파르티스 아게 |
오파투무맙을 사용한 다발성 경화증의 치료 요법 및 방법
|
EP3515936A1
(de)
|
2016-09-23 |
2019-07-31 |
Elstar Therapeutics, Inc. |
Multispezifische antikörpermoleküle mit lambda- und kappa- leichtketten
|
IL307684A
(en)
|
2016-09-29 |
2023-12-01 |
Amgen Inc |
Low viscosity antigen binding proteins and methods for their preparation
|
BR112019006778A2
(pt)
|
2016-10-18 |
2019-10-15 |
Seattle Genetics Inc |
Composição de conjugado de aglutinante-fármaco, formulação, uso da mesma, método para preparar uma composição ou composto de conjugado de aglutinantefármaco,e, composto de ligante de fármaco
|
JP7062669B2
(ja)
|
2016-12-23 |
2022-05-06 |
ブリストル-マイヤーズ スクイブ カンパニー |
改善されたバイオアナリシス特性およびバイオプロセシング特性のための、治療用免疫グロブリンg4の設計
|
CN110366557B
(zh)
|
2016-12-23 |
2024-04-09 |
威特拉公司 |
结合多肽及其制备方法
|
US11168147B2
(en)
|
2016-12-23 |
2021-11-09 |
Novartis Ag |
Factor XI antibodies and methods of use
|
US20180207267A1
(en)
|
2017-01-06 |
2018-07-26 |
Scholar Rock, Inc. |
Isoform-specific, context-permissive tgfb1 inhibitors and use thereof
|
WO2018129395A1
(en)
|
2017-01-06 |
2018-07-12 |
Scholar Rock, Inc. |
Methods for treating metabolic diseases by inhibiting myostatin activation
|
EP4218817A3
(de)
|
2017-01-06 |
2023-09-06 |
Scholar Rock, Inc. |
Verfahren zur behandlung von stoffwechselerkrankungen durch hemmung der myostatinaktivierung
|
US11890319B2
(en)
|
2017-01-18 |
2024-02-06 |
Visterra, Inc. |
Antibody molecule-drug conjugates and uses thereof
|
WO2018138591A1
(en)
|
2017-01-24 |
2018-08-02 |
Pfizer Inc. |
Calicheamicin derivatives and antibody drug conjugates thereof
|
CN110234658B
(zh)
|
2017-01-31 |
2024-03-12 |
辉瑞大药厂 |
脑膜炎奈瑟菌组合物及其使用方法
|
JOP20190189A1
(ar)
|
2017-02-02 |
2019-08-01 |
Amgen Res Munich Gmbh |
تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
|
US20180221476A1
(en)
|
2017-02-06 |
2018-08-09 |
Oncoquest Nc. |
Treatment of cancer with therapeutic monoclonal antibody specific for a tumor associated antigen and an immune adjuvant
|
US20200291089A1
(en)
|
2017-02-16 |
2020-09-17 |
Elstar Therapeutics, Inc. |
Multifunctional molecules comprising a trimeric ligand and uses thereof
|
WO2018158719A1
(en)
|
2017-03-02 |
2018-09-07 |
Novartis Ag |
Engineered heterodimeric proteins
|
JP7048629B2
(ja)
|
2017-03-10 |
2022-04-05 |
エンベラ ニューロセラピューティクス,インコーポレイティド |
医薬組成物およびその使用
|
US20200056190A1
(en)
|
2017-03-16 |
2020-02-20 |
Pfizer Inc. |
Tyrosine prototrophy
|
IL269398B2
(en)
|
2017-03-24 |
2024-05-01 |
Seagen Inc |
A process for the preparation of glucuronide-drug binders and their intermediates
|
CA3057676A1
(en)
|
2017-03-24 |
2018-09-27 |
The Regents Of The University Of California |
Proteoglycan irregularities in abnormal fibroblasts and therapies based therefrom
|
WO2018187227A1
(en)
|
2017-04-03 |
2018-10-11 |
Concologie, Inc. |
Methods for treating cancer using ps-targeting antibodies with immuno-oncology agents
|
US20200071417A1
(en)
|
2017-04-19 |
2020-03-05 |
Elstar Therapeutics, Inc. |
Multispecific molecules and uses thereof
|
US11203629B2
(en)
|
2017-04-22 |
2021-12-21 |
Immunomic Therapeutics, Inc. |
LAMP constructs
|
KR20190141181A
(ko)
|
2017-04-27 |
2019-12-23 |
시애틀 지네틱스, 인크. |
사차화된 니코틴아미드 아데닌 다이뉴클레오타이드 구제 경로 억제제 콘쥬게이트
|
WO2018201051A1
(en)
|
2017-04-28 |
2018-11-01 |
Novartis Ag |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
WO2018201047A1
(en)
|
2017-04-28 |
2018-11-01 |
Elstar Therapeutics, Inc. |
Multispecific molecules comprising a non-immunoglobulin heterodimerization domain and uses thereof
|
MA48461A
(fr)
|
2017-04-28 |
2020-03-04 |
Amgen Inc |
Excipients pour réduire la viscosité de formulations d'anticorps et compositions de formulation
|
AU2018263923A1
(en)
|
2017-05-02 |
2019-10-31 |
Immunomic Therapeutics, Inc. |
LAMP (lysosomal associated membrane protein) constructs comprising cancer antigens
|
MA48763A
(fr)
|
2017-05-05 |
2020-04-08 |
Amgen Inc |
Composition pharmaceutique comprenant des constructions d'anticorps bispécifiques pour un stockage et une administration améliorés
|
CA3063344A1
(en)
|
2017-05-23 |
2018-11-29 |
Helmholtz Zentrum Munchen - Deutsches Forschungszentrum Fur Gesundheit Und Umwelt (Gmbh) |
Novel cd73 antibody, preparation and uses thereof
|
EP3630836A1
(de)
|
2017-05-31 |
2020-04-08 |
Elstar Therapeutics, Inc. |
Multispezifische moleküle, die an myeloproliferatives leukämie (mlp)-protein binden, und deren verwendungen
|
PE20200717A1
(es)
|
2017-06-22 |
2020-07-21 |
Novartis Ag |
Moleculas de anticuerpo que se unen a cd73 y usos de las mismas
|
EP3642240A1
(de)
|
2017-06-22 |
2020-04-29 |
Novartis AG |
Antikörpermoleküle gegen cd73 und verwendungen davon
|
EP3645037A1
(de)
|
2017-06-27 |
2020-05-06 |
Novartis AG |
Dosierungsschema für anti-tim-3-antikörper und verwendungen davon
|
EP3431496A1
(de)
|
2017-07-19 |
2019-01-23 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Anti-isoasp7-amyloid-beta-antikörper und verwendungen davon
|
US20200172617A1
(en)
|
2017-07-20 |
2020-06-04 |
Novartis Ag |
Dosage regimens of anti-lag-3 antibodies and uses thereof
|
EP3658583A1
(de)
|
2017-07-28 |
2020-06-03 |
Scholar Rock, Inc. |
Ltbp-komplex-spezifische inhibitoren von tgf-beta 1 und verwendungen davon
|
WO2019035938A1
(en)
|
2017-08-16 |
2019-02-21 |
Elstar Therapeutics, Inc. |
MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
|
DK3681483T3
(da)
|
2017-09-15 |
2022-08-29 |
Amgen Inc |
Fremgangsmåde til lyofiliseret farmaceutisk formulering af et terapeutisk protein
|
KR20200047702A
(ko)
|
2017-09-15 |
2020-05-07 |
브리스톨-마이어스 스큅 컴퍼니 |
관심 폴리펩티드 대규모 생산 동안의 온라인 바이오매스 정전용량 모니터링
|
ES2759622T3
(es)
|
2017-10-02 |
2020-05-11 |
Certest Biotec S L |
Anticuerpos anti-Dps y dispositivos de prueba para la detección de bacterias del género Campylobacter
|
US11945868B2
(en)
|
2017-10-02 |
2024-04-02 |
Visterra, Inc. |
Antibody molecules to CD138 and uses thereof
|
US10640508B2
(en)
|
2017-10-13 |
2020-05-05 |
Massachusetts Institute Of Technology |
Diazene directed modular synthesis of compounds with quaternary carbon centers
|
BR112020007046A2
(pt)
|
2017-10-19 |
2020-11-17 |
Debiopharm International S.A. |
produto de combinação para o tratamento do câncer
|
US20200283485A1
(en)
|
2017-10-20 |
2020-09-10 |
Institut Curie |
Hook fusion protein for regulating the cellular trafficking of a target protein
|
EP3697809A1
(de)
|
2017-10-20 |
2020-08-26 |
Institut Curie |
Für rush angepasste dap10/12-basierte cars
|
JP2021502125A
(ja)
|
2017-11-09 |
2021-01-28 |
ピンテオン セラピューティクス インコーポレイテッド |
ヒト化コンホメーション特異的リン酸化タウ抗体の作製および使用のための方法および組成物
|
MX2020004756A
(es)
|
2017-11-16 |
2020-08-20 |
Novartis Ag |
Terapias de combinacion.
|
US20200377571A1
(en)
|
2017-12-08 |
2020-12-03 |
Elstar Therapeutics, Inc. |
Multispecific molecules and uses thereof
|
EA202091422A1
(ru)
|
2017-12-11 |
2020-08-28 |
Эмджен Инк. |
Способ непрерывного производства продуктов на основе биспецифических антител
|
TW201940518A
(zh)
|
2017-12-29 |
2019-10-16 |
美商安進公司 |
針對muc17和cd3之雙特異性抗體構建體
|
BR112020013405A2
(pt)
|
2018-01-25 |
2020-12-01 |
Acm Biolabs Pte Ltd. |
polimerossomas compreendendo um antígeno encapsulado solúvel, assim como métodos de sua fabricação e uso
|
WO2019150309A1
(en)
|
2018-02-02 |
2019-08-08 |
Hammack Scott |
Modulators of gpr68 and uses thereof for treating and preventing diseases
|
SG11202007540SA
(en)
|
2018-02-20 |
2020-09-29 |
Seattle Genetics Inc |
Hydrophobic auristatin f compounds and conjugates thereof
|
US11401336B2
(en)
|
2018-02-21 |
2022-08-02 |
Celgene Corporation |
BCMA-binding antibodies and uses thereof
|
EP3530282A1
(de)
|
2018-02-27 |
2019-08-28 |
Diaccurate |
Therapeutische verfahren
|
US20210009711A1
(en)
|
2018-03-14 |
2021-01-14 |
Elstar Therapeutics, Inc. |
Multifunctional molecules and uses thereof
|
WO2019178362A1
(en)
|
2018-03-14 |
2019-09-19 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
US20210010055A1
(en)
|
2018-03-16 |
2021-01-14 |
Bristol-Myers Squibb Company |
Metabolic enzyme activity and disulfide bond reduction during protein production
|
LT3775909T
(lt)
|
2018-03-26 |
2023-08-10 |
Glycanostics S.R.O. |
Priemonės ir būdai, skirti baltymo glikozilinimo profilio nustatymui
|
US20210147547A1
(en)
|
2018-04-13 |
2021-05-20 |
Novartis Ag |
Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
|
KR20210027254A
(ko)
|
2018-04-24 |
2021-03-10 |
앰프소스 바이오파마 상하이 인코포레이티드 |
Tim-3에 대한 항체 및 그의 용도
|
WO2019222281A1
(en)
|
2018-05-15 |
2019-11-21 |
Immunomic Therapeutics, Inc |
Improved lamp constructs comprising allergens
|
TW202015726A
(zh)
|
2018-05-30 |
2020-05-01 |
瑞士商諾華公司 |
Entpd2抗體、組合療法、及使用該等抗體和組合療法之方法
|
US20210214459A1
(en)
|
2018-05-31 |
2021-07-15 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
BR112020024351A2
(pt)
|
2018-06-01 |
2021-02-23 |
Novartis Ag |
moléculas de ligação contra bcma e usos das mesmas
|
AU2019282264A1
(en)
|
2018-06-05 |
2020-11-26 |
Amgen Inc. |
Modulating antibody dependent cellular phagocytosis
|
TW202015740A
(zh)
|
2018-06-07 |
2020-05-01 |
美商西雅圖遺傳學公司 |
喜樹鹼結合物
|
PE20210418A1
(es)
|
2018-06-19 |
2021-03-08 |
Atarga Llc |
Moleculas de anticuerpo de componente de complemento 5 y sus usos
|
TW202016144A
(zh)
|
2018-06-21 |
2020-05-01 |
日商第一三共股份有限公司 |
包括cd3抗原結合片段之組成物及其用途
|
EP3818083A2
(de)
|
2018-07-03 |
2021-05-12 |
Elstar Therapeutics, Inc. |
Anti-tcr-antikörpermoleküle und ihre verwendungen
|
WO2020008083A1
(es)
|
2018-07-05 |
2020-01-09 |
Consejo Superior De Investigaciones Científicas |
Diana terapéutica en receptores de quimiocinas para la selección de compuestos útiles para el tratamiento de procesos patológicos que implican la señalización de quimiocinas
|
MA52165A
(fr)
|
2018-07-11 |
2021-06-02 |
Scholar Rock Inc |
Inhibiteurs sélectifs de l'isoforme tgfbeta1 et utilisation associée
|
EP3820896A1
(de)
|
2018-07-11 |
2021-05-19 |
Scholar Rock, Inc. |
Tgfbeta1-inhibitoren und verwendung davon
|
TW202005981A
(zh)
|
2018-07-11 |
2020-02-01 |
美商供石公司 |
高親和性、異構體選擇性之TGFβ1抑制劑及其用途
|
WO2020021465A1
(en)
|
2018-07-25 |
2020-01-30 |
Advanced Accelerator Applications (Italy) S.R.L. |
Method of treatment of neuroendocrine tumors
|
CN112771075A
(zh)
|
2018-07-30 |
2021-05-07 |
安进研发(慕尼黑)股份有限公司 |
结合至cd33和cd3的双特异性抗体构建体的延长施用
|
PE20211400A1
(es)
|
2018-08-03 |
2021-07-27 |
Amgen Res Munich Gmbh |
Constructos de anticuerpos para cldn18.2 y cd3
|
WO2020043670A1
(en)
|
2018-08-27 |
2020-03-05 |
Affimed Gmbh |
Cryopreserved nk cells preloaded with an antibody construct
|
CA3110530A1
(en)
|
2018-09-11 |
2020-03-19 |
Amgen Inc. |
Methods of modulating antibody-dependent cell-mediated cytotoxicity
|
EP3849600A1
(de)
|
2018-09-12 |
2021-07-21 |
ACM Biolabs Pte Ltd |
Polymersome mit einem kovalent gebundenen antigen sowie verfahren zu deren herstellung und verwendung
|
WO2020053808A1
(en)
|
2018-09-12 |
2020-03-19 |
Georg Dewald |
Method of diagnosing vasoregulatory disorders
|
JP7465272B2
(ja)
|
2018-09-27 |
2024-04-10 |
マレンゴ・セラピューティクス,インコーポレーテッド |
Csf1r/ccr2多特異性抗体
|
EP3856781A1
(de)
|
2018-09-28 |
2021-08-04 |
Amgen Inc. |
Antikörper gegen lösliches bcma
|
AU2019354101A1
(en)
|
2018-10-05 |
2021-04-15 |
Bavarian Nordic A/S |
Combination therapy for treating cancer with an intravenous administration of a recombinant mva and an immune checkpoint antagonist or agonist
|
MX2021003976A
(es)
|
2018-10-11 |
2021-05-27 |
Amgen Inc |
Procesamiento posterior de constructos de anticuerpos biespecificos.
|
UY38407A
(es)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
Anticuerpos estabilizadores de trem2
|
SG11202104010PA
(en)
|
2018-10-23 |
2021-05-28 |
Scholar Rock Inc |
Rgmc-selective inhibitors and use thereof
|
WO2020104531A1
(en)
|
2018-11-20 |
2020-05-28 |
Bavarian Nordic A/S |
Therapy for treating cancer with an intratumoral and/or intravenous administration of a recombinant mva encoding 4-1bbl (cd137l) and/or cd40l
|
WO2020115655A1
(en)
|
2018-12-06 |
2020-06-11 |
Pfizer Inc. |
Cells with reduced inhibitor production and methods of use thereof
|
WO2020128892A1
(en)
|
2018-12-20 |
2020-06-25 |
Novartis Ag |
Extended low dose regimens for mdm2 inhibitors
|
PE20220279A1
(es)
|
2019-01-30 |
2022-02-25 |
Scholar Rock Inc |
Inhibidores especificos del complejo de ltbp de tgf beta y usos de los mismos
|
US20220290128A1
(en)
|
2019-02-04 |
2022-09-15 |
National University Corporation Ehime University |
CAR LIBRARY AND scFv MANUFACTURING METHOD
|
EP3693063A1
(de)
|
2019-02-06 |
2020-08-12 |
Diaccurate |
Verfahren und zusammensetzungen zur behandlung von krebs
|
EP3924739A1
(de)
|
2019-02-12 |
2021-12-22 |
Biogen MA Inc. |
Biomarker von progressiver multifokaler leukoenzephalopathie
|
US11478553B2
(en)
|
2019-02-15 |
2022-10-25 |
Wuxi Biologies Ireland Limited |
Process for preparing antibody-drug conjugates with improved homogeneity
|
US10871640B2
(en)
|
2019-02-15 |
2020-12-22 |
Perkinelmer Cellular Technologies Germany Gmbh |
Methods and systems for automated imaging of three-dimensional objects
|
US11254736B2
(en)
|
2019-02-15 |
2022-02-22 |
Integral Molecular, Inc. |
Antibodies comprising a common light chain and uses thereof
|
SG11202108281UA
(en)
|
2019-02-15 |
2021-08-30 |
Integral Molecular Inc |
Claudin 6 antibodies and uses thereof
|
JP2022521750A
(ja)
|
2019-02-21 |
2022-04-12 |
マレンゴ・セラピューティクス,インコーポレーテッド |
カルレティキュリンに結合する多機能性分子およびその使用
|
CA3130754A1
(en)
|
2019-02-21 |
2020-08-27 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to t cell related cancer cells and uses thereof
|
JP2022522662A
(ja)
|
2019-02-21 |
2022-04-20 |
マレンゴ・セラピューティクス,インコーポレーテッド |
T細胞に結合する多機能性分子および自己免疫障害を処置するためのその使用
|
CA3131014A1
(en)
|
2019-02-21 |
2020-08-27 |
Andreas Loew |
Anti-tcr antibody molecules and uses thereof
|
CA3130508A1
(en)
|
2019-02-21 |
2020-08-27 |
Marengo Therapeutics, Inc. |
Antibody molecules that bind to nkp30 and uses thereof
|
AU2020253833A1
(en)
|
2019-03-29 |
2021-10-28 |
Atarga, Llc |
Anti FGF23 antibody
|
US20220289854A1
(en)
|
2019-04-30 |
2022-09-15 |
Dana-Farber Cancer Institute, Inc. |
Methods for treating cancer using combinations of anti-cx3cr1 and immune checkpoint blockade agents
|
TW202108177A
(zh)
|
2019-05-10 |
2021-03-01 |
日商武田藥品工業股份有限公司 |
抗體藥物結合物
|
CU20210096A7
(es)
|
2019-05-21 |
2022-06-06 |
Novartis Ag |
Moléculas de unión a cd19
|
US20230071196A1
(en)
|
2019-05-21 |
2023-03-09 |
Novartis Ag |
Variant cd58 domains and uses thereof
|
CA3137494A1
(en)
|
2019-06-13 |
2020-12-17 |
Amgen Inc. |
Automated biomass-based perfusion control in the manufacturing of biologics
|
BR112021025421A2
(pt)
|
2019-06-17 |
2022-02-01 |
Visterra Inc |
Moléculas de anticorpo humanizado para cd138 e os usos dos mesmos
|
WO2021016062A1
(en)
|
2019-07-19 |
2021-01-28 |
The Children's Hospital Of Philadelphia |
Chimeric antigen receptors containing glypican 2 binding domains
|
JP7483857B2
(ja)
|
2019-07-26 |
2024-05-15 |
ビステラ, インコーポレイテッド |
インターロイキン-2作用物質およびその使用
|
EP4031658A1
(de)
|
2019-08-07 |
2022-07-27 |
DB Biotech, AS |
Verbesserte meerrettichperoxidase-polypeptide
|
WO2021044009A1
(en)
|
2019-09-04 |
2021-03-11 |
Deutsches Zentrum Für Neurodegenerative Erkrankungen E.V. (Dzne) |
Herv inhibitors for use in treating tauopathies
|
JP2022547135A
(ja)
|
2019-09-10 |
2022-11-10 |
アムジエン・インコーポレーテツド |
増強されたプロテインl捕捉動的結合容量を有する二重特異性抗原結合ポリペプチドの精製方法
|
CN114502590A
(zh)
|
2019-09-18 |
2022-05-13 |
诺华股份有限公司 |
Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法
|
TW202124446A
(zh)
|
2019-09-18 |
2021-07-01 |
瑞士商諾華公司 |
與entpd2抗體之組合療法
|
KR20220084056A
(ko)
|
2019-09-19 |
2022-06-21 |
씨젠 인크. |
내재화된 생물학적 활성 화합물 컨쥬게이트로부터의 선택적 약물 방출
|
CA3152316A1
(en)
|
2019-10-04 |
2021-04-08 |
Scott C. Jeffrey |
Camptothecin peptide conjugates
|
WO2021067820A1
(en)
|
2019-10-04 |
2021-04-08 |
Seagen Inc. |
Formulation of antibody-drug conjugate
|
CA3153850A1
(en)
|
2019-10-18 |
2021-04-22 |
Teri Heiland |
Improved lamp constructs comprising cancer antigens
|
BR112022007376A2
(pt)
|
2019-10-21 |
2022-07-05 |
Novartis Ag |
Terapias de combinação com venetoclax e inibidores de tim-3
|
WO2021079195A1
(en)
|
2019-10-21 |
2021-04-29 |
Novartis Ag |
Tim-3 inhibitors and uses thereof
|
US20220396599A1
(en)
|
2019-11-13 |
2022-12-15 |
Amgen Inc. |
Method for Reduced Aggregate Formation in Downstream Processing of Bispecific Antigen-Binding Molecules
|
KR20220106775A
(ko)
|
2019-11-20 |
2022-07-29 |
버베리안 노딕 에이/에스 |
암 치료를 위한 종양내 및/또는 정맥내 투여를 위한 재조합 mva 바이러스
|
WO2021123996A1
(en)
|
2019-12-20 |
2021-06-24 |
Novartis Ag |
Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
|
UY38995A
(es)
|
2019-12-20 |
2021-06-30 |
Amgen Inc |
Constructos de anticuerpo multiespecíficos agonistas de cd40 dirigidos a mesotelina para el tratamiento de tumores sólidos
|
AU2020414409A1
(en)
|
2019-12-27 |
2022-06-16 |
Affimed Gmbh |
Method for the production of bispecific FcyRIIl x CD30 antibody construct
|
TW202138388A
(zh)
|
2019-12-30 |
2021-10-16 |
美商西根公司 |
以非海藻糖苷化抗-cd70抗體治療癌症之方法
|
EP4084821A4
(de)
|
2020-01-03 |
2024-04-24 |
Marengo Therapeutics, Inc. |
An cd33 bindende multifunktionsmoleküle und ihre verwendungen
|
EP4087659A2
(de)
|
2020-01-11 |
2022-11-16 |
Scholar Rock, Inc. |
Tgf-beta-inhibitoren und verwendung davon
|
AU2021205433A1
(en)
|
2020-01-11 |
2022-08-18 |
Scholar Rock, Inc. |
Tgfß inhibitors and use thereof
|
TW202140553A
(zh)
|
2020-01-13 |
2021-11-01 |
美商威特拉公司 |
C5ar1抗體分子及其用途
|
JP2023510393A
(ja)
|
2020-01-17 |
2023-03-13 |
ノバルティス アーゲー |
骨髄異形成症候群または慢性骨髄単球性白血病の処置に使用するためのtim-3阻害剤と低メチル化剤とを含む組合せ
|
WO2021150824A1
(en)
|
2020-01-22 |
2021-07-29 |
Amgen Research (Munich) Gmbh |
Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
|
WO2021173773A1
(en)
|
2020-02-25 |
2021-09-02 |
Mediboston, Inc. |
Camptothecin derivatives and conjugates thereof
|
TW202200615A
(zh)
|
2020-03-12 |
2022-01-01 |
美商安進公司 |
用於治療和預防患者的crs之方法
|
KR20220155338A
(ko)
|
2020-03-19 |
2022-11-22 |
암젠 인크 |
뮤신 17에 대한 항체 및 이의 용도
|
US11815513B2
(en)
|
2020-04-01 |
2023-11-14 |
Institut Pasteur |
Severe acute respiratory syndrome (SARS)-associated coronavirus diagnostics
|
US20210311054A1
(en)
|
2020-04-01 |
2021-10-07 |
Institut Pasteur |
Severe acute respiratory syndrome (sars) - associated coronavirus diagnostics
|
CN116710146A
(zh)
|
2020-04-03 |
2023-09-05 |
威特拉公司 |
抗体分子-药物偶联物及其用途
|
US20230173093A1
(en)
|
2020-04-10 |
2023-06-08 |
Seagen Inc. |
Charge variant linkers
|
WO2021209824A1
(en)
|
2020-04-17 |
2021-10-21 |
Institut Pasteur |
Methods and products for serological analysis of sars-cov-2 infection
|
JP2023523760A
(ja)
|
2020-05-01 |
2023-06-07 |
ノバルティス アーゲー |
免疫グロブリン変異体
|
JP2023523794A
(ja)
|
2020-05-01 |
2023-06-07 |
ノバルティス アーゲー |
人工操作免疫グロブリン
|
CA3183756A1
(en)
|
2020-05-19 |
2021-11-25 |
Amgen Inc. |
Mageb2 binding constructs
|
WO2021239666A1
(en)
|
2020-05-26 |
2021-12-02 |
Diaccurate |
Therapeutic methods
|
EP4157874A2
(de)
|
2020-05-29 |
2023-04-05 |
Amgen Inc. |
Die nebenwirkungen mindernde verabreichung eines bispezifischen antikörperkonstrukts, das an cd33 und cd3 bindet
|
CN115803062A
(zh)
|
2020-06-03 |
2023-03-14 |
博泰康医药公司 |
滋养层细胞表面抗原2(trop-2)抗体
|
BR112022026639A2
(pt)
|
2020-06-24 |
2023-05-09 |
Visterra Inc |
Moléculas de anticorpos para april e seus usos
|
WO2022010797A2
(en)
|
2020-07-07 |
2022-01-13 |
Bionecure Therapeutics, Inc. |
Novel maytansinoids as adc payloads and their use for the treatment of cancer
|
WO2022008976A1
(en)
|
2020-07-10 |
2022-01-13 |
Institut Pasteur |
Use of gdf11 to diagnose and treat anxiety and depression
|
WO2022014703A1
(ja)
|
2020-07-17 |
2022-01-20 |
田辺三菱製薬株式会社 |
筋疾患の予防または治療剤
|
WO2022026592A2
(en)
|
2020-07-28 |
2022-02-03 |
Celltas Bio, Inc. |
Antibody molecules to coronavirus and uses thereof
|
KR20230074487A
(ko)
|
2020-08-26 |
2023-05-30 |
마렝고 테라퓨틱스, 인크. |
Trbc1 또는 trbc2를 검출하는 방법
|
AU2021331076A1
(en)
|
2020-08-26 |
2023-04-06 |
Marengo Therapeutics, Inc. |
Antibody molecules that bind to NKp30 and uses thereof
|
AU2021331075A1
(en)
|
2020-08-26 |
2023-04-06 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
US20230338587A1
(en)
|
2020-08-31 |
2023-10-26 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
WO2022043557A1
(en)
|
2020-08-31 |
2022-03-03 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
CA3192526A1
(en)
|
2020-09-04 |
2022-03-10 |
Rutgers, The State University Of New Jersey |
Sars-cov-2 vaccines and antibodies
|
US20240053339A1
(en)
|
2020-09-21 |
2024-02-15 |
Theravectys |
High throughput methods and products for sars-cov-2 sero-neutralization assay
|
WO2022074206A1
(en)
|
2020-10-08 |
2022-04-14 |
Affimed Gmbh |
Trispecific binders
|
WO2022081436A1
(en)
|
2020-10-15 |
2022-04-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibody specific for sars-cov-2 receptor binding domain and therapeutic methods
|
WO2022087274A1
(en)
|
2020-10-21 |
2022-04-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibodies that neutralize type-i interferon (ifn) activity
|
WO2022096716A2
(en)
|
2020-11-06 |
2022-05-12 |
Amgen Inc. |
Multitargeting bispecific antigen-binding molecules of increased selectivity
|
KR20230104651A
(ko)
|
2020-11-06 |
2023-07-10 |
노파르티스 아게 |
Cd19 결합 분자 및 이의 용도
|
IL302412A
(en)
|
2020-11-06 |
2023-06-01 |
Novartis Ag |
Anti-CD19 and B-cell targeting agent combination therapy for the treatment of B-cell malignancies
|
AU2021374036A1
(en)
|
2020-11-06 |
2023-06-08 |
Amgen Inc. |
Polypeptide constructs selectively binding to cldn6 and cd3
|
US20230406929A1
(en)
|
2020-11-06 |
2023-12-21 |
Amgen Inc. |
Polypeptide constructs binding to cd3
|
KR20230098335A
(ko)
|
2020-11-06 |
2023-07-03 |
암젠 인크 |
클리핑 비율이 감소된 항원 결합 도메인
|
US20220168330A1
(en)
|
2020-11-09 |
2022-06-02 |
Takeda Pharmaceutical Company Limited |
Antibody drug conjugates
|
AU2021391924A1
(en)
|
2020-12-04 |
2023-06-22 |
The General Hospital Corporation |
Methods of using interleukin-2 agents
|
JP2024503657A
(ja)
|
2021-01-13 |
2024-01-26 |
メモリアル スローン-ケタリング キャンサー センター |
抗体-ピロロベンゾジアゼピン誘導体コンジュゲート
|
MX2023008285A
(es)
|
2021-01-13 |
2023-09-12 |
Memorial Sloan Kettering Cancer Center |
Conjugado de anticuerpo anti-dll3-farmaco.
|
BR112023014128A2
(pt)
|
2021-01-15 |
2023-10-31 |
Seagen Inc |
Conjugados de anticorpo-fármaco imunomodulatórios
|
WO2022159575A1
(en)
|
2021-01-20 |
2022-07-28 |
Bioentre Llc |
Ctla4-binding proteins and methods of treating cancer
|
US20220226442A1
(en)
|
2021-01-20 |
2022-07-21 |
Visterra, Inc. |
Interleukin-2 agents and uses thereof
|
JP2024505049A
(ja)
|
2021-01-29 |
2024-02-02 |
ノバルティス アーゲー |
抗cd73及び抗entpd2抗体のための投与方式並びにその使用
|
KR20230152679A
(ko)
|
2021-02-03 |
2023-11-03 |
씨젠 인크. |
면역자극 화합물 및 접합체
|
WO2022182872A2
(en)
|
2021-02-24 |
2022-09-01 |
Alladapt Immunotherapeutics, Inc. |
Compositions and methods for identification of cross-reactive allergenic proteins and treatment of allergies
|
US20230091653A1
(en)
|
2021-03-18 |
2023-03-23 |
Seagen Inc. |
Selective drug release from internalized conjugates of biologically active compounds
|
JP2024511373A
(ja)
|
2021-03-18 |
2024-03-13 |
ノバルティス アーゲー |
がんのためのバイオマーカーおよびその使用
|
MX2023010819A
(es)
|
2021-03-18 |
2023-09-28 |
Seagen Inc |
Liberacion selectiva de farmacos a partir de conjugados internalizados de compuestos biologicamente activos.
|
WO2022204581A2
(en)
|
2021-03-26 |
2022-09-29 |
Scholar Rock, Inc. |
Tgf-beta inhibitors and use thereof
|
AU2022246675A1
(en)
|
2021-04-02 |
2023-10-19 |
Amgen Inc. |
Mageb2 binding constructs
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途
|
KR20240004462A
(ko)
|
2021-04-08 |
2024-01-11 |
마렝고 테라퓨틱스, 인크. |
Tcr에 결합하는 다기능성 분자 및 이의 용도
|
CA3214934A1
(en)
|
2021-04-12 |
2022-10-20 |
Madhavan Nallani |
Polymersomes comprising a soluble encapsulated polynucleotide and an ionizable lipid as well as methods of making and uses thereof
|
IL307672A
(en)
|
2021-05-06 |
2023-12-01 |
Amgen Res Munich Gmbh |
CD20 and CD22 targeting antigen-binding molecules for use in proliferative diseases
|
AU2022283467A1
(en)
|
2021-05-28 |
2023-12-07 |
Seagen Inc. |
Anthracycline antibody conjugates
|
EP4348260A2
(de)
|
2021-06-03 |
2024-04-10 |
Scholar Rock, Inc. |
Tgf-beta inhibitoren und deren therapeutische verwendung
|
CA3221555A1
(en)
|
2021-06-23 |
2022-12-29 |
Kimberly LONG |
A myostatin pathway inhibitor in combination with a glp-1 pathway activator for use in treating metabolic disorders
|
KR20240025597A
(ko)
|
2021-06-29 |
2024-02-27 |
씨젠 인크. |
비푸코실화 항-cd70 항체 및 cd47 길항제의 조합으로 암을 치료하는 방법
|
AU2022310862A1
(en)
|
2021-07-14 |
2024-02-01 |
Regeneron Pharmaceuticals, Inc. |
Engineered t cell receptors fused to binding domains from antibodies
|
AU2022320948A1
(en)
|
2021-07-30 |
2024-01-18 |
Affimed Gmbh |
Duplexbodies
|
AU2022335718A1
(en)
|
2021-08-26 |
2024-03-28 |
Glycanostics S.R.O |
Glycoprotein biomarkers for diagnosing cancer
|
CA3231890A1
(en)
|
2021-09-14 |
2023-03-23 |
Jan Tkac |
Use of lectins to determine mammaglobin-a glycoforms in breast cancer
|
WO2023044483A2
(en)
|
2021-09-20 |
2023-03-23 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
CA3233696A1
(en)
|
2021-11-03 |
2023-05-11 |
Joachim Koch |
Bispecific cd16a binders
|
WO2023079493A1
(en)
|
2021-11-03 |
2023-05-11 |
Affimed Gmbh |
Bispecific cd16a binders
|
WO2023079058A1
(en)
|
2021-11-05 |
2023-05-11 |
Yokogawa Insilico Biotechnology Gmbh |
Cell culture with reduced production of lactate
|
WO2023092004A1
(en)
|
2021-11-17 |
2023-05-25 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
US20230348614A1
(en)
|
2021-11-24 |
2023-11-02 |
Visterra, Inc. |
Engineered antibody molecules to cd138 and uses thereof
|
WO2023102463A1
(en)
|
2021-12-01 |
2023-06-08 |
Visterra, Inc. |
Methods of using interleukin-2 agents
|
WO2023118508A1
(en)
|
2021-12-23 |
2023-06-29 |
Bavarian Nordic A/S |
Recombinant mva viruses for intraperitoneal administration for treating cancer
|
WO2023148598A1
(en)
|
2022-02-02 |
2023-08-10 |
Pfizer Inc. |
Cysteine prototrophy
|
US20230383010A1
(en)
|
2022-02-07 |
2023-11-30 |
Visterra, Inc. |
Anti-idiotype antibody molecules and uses thereof
|
TW202400137A
(zh)
|
2022-03-17 |
2024-01-01 |
美商思進公司 |
喜樹鹼偶聯物
|
WO2023201201A1
(en)
|
2022-04-10 |
2023-10-19 |
Immunomic Therapeutics, Inc. |
Bicistronic lamp constructs comprising immune response enhancing genes and methods of use thereof
|
TW202400637A
(zh)
|
2022-04-25 |
2024-01-01 |
美商威特拉公司 |
April之抗體分子及其用途
|
WO2023215740A1
(en)
|
2022-05-06 |
2023-11-09 |
Seagen Inc. |
Immunomodulatory antibody-drug conjugates
|
TW202346368A
(zh)
|
2022-05-12 |
2023-12-01 |
德商安美基研究(慕尼黑)公司 |
具有增加的選擇性的多鏈多靶向性雙特異性抗原結合分子
|
WO2023220695A2
(en)
|
2022-05-13 |
2023-11-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
WO2023223092A1
(en)
|
2022-05-18 |
2023-11-23 |
Institut Pasteur |
Identification of a human circovirus
|
WO2023240287A1
(en)
|
2022-06-10 |
2023-12-14 |
Bioentre Llc |
Combinations of ctla4 binding proteins and methods of treating cancer
|
EP4296279A1
(de)
|
2022-06-23 |
2023-12-27 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Anti-transthyretin(ttr)-bindende proteine und ihre verwendungen
|
WO2024023735A1
(en)
|
2022-07-27 |
2024-02-01 |
Mediboston Limited |
Auristatin derivatives and conjugates thereof
|
WO2024030577A1
(en)
|
2022-08-03 |
2024-02-08 |
Seagen Inc. |
Immunostimulatory anti-pd-l1-drug conjugates
|
WO2024030976A2
(en)
|
2022-08-03 |
2024-02-08 |
Voyager Therapeutics, Inc. |
Compositions and methods for crossing the blood brain barrier
|
EP4321522A1
(de)
|
2022-08-12 |
2024-02-14 |
Seagen Inc. |
Zytotoxische verbindungen und konjugate davon
|
WO2024059675A2
(en)
|
2022-09-14 |
2024-03-21 |
Amgen Inc. |
Bispecific molecule stabilizing composition
|
WO2024129756A1
(en)
|
2022-12-13 |
2024-06-20 |
Seagen Inc. |
Site-specific engineered cysteine antibody drug conjugates
|